Document:

Prepared by R.R. Donnelley Financial -- EX-10.6

 Exhibit 10.6 

VIROBAY, INC. 

2014 EMPLOYEE STOCK PURCHASE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS:
OCTOBER 1, 2014 
 APPROVED BY THE STOCKHOLDERS:
OCTOBER 1, 2014 
 IPO DATE/EFFECTIVE DATE: OCTOBER
[    ], 2014 
 1. GENERAL; PURPOSE. 

(a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an
opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. 

(b) The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new
Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. 
 2.
ADMINISTRATION. 
 (a) The Board will administer the Plan unless and until the Board delegates administration of
the Plan to a Committee or Committees, as provided in Section 2(c). 
 (b) The Board will have the power, subject to, and
within the limitations of, the express provisions of the Plan: 
 (i) To determine how and when Purchase Rights will be granted and
the provisions of each Offering (which need not be identical). 
 (ii) To designate from time to time which Related Corporations of
the Company will be eligible to participate in the Plan. 
 (iii) To construe and interpret the Plan and Purchase Rights, and to
establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make
the Plan fully effective. 
 (iv) To settle all controversies regarding the Plan and Purchase Rights granted under the Plan. 

(v) To suspend or terminate the Plan at any time as provided in Section 12. 

(vi) To amend the Plan at any time as provided in Section 12. 

(vii) Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of
the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. 

 (viii) To adopt such procedures and sub-plans as are necessary or appropriate to permit
participation in the Plan by Employees who are foreign nationals or employed outside the United States. 
 (c) The Board may delegate
some or all of the administration of the Plan to a Committee or Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that
have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or
subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and
may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and
expediency that may arise in the administration of the Plan. 
 (d) All determinations, interpretations and constructions made
by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 
 3.
SHARES OF COMMON STOCK SUBJECT TO THE PLAN. 

(a) Subject to the provisions of Section 11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock
that may be issued under the Plan will not exceed 150,000 shares of Common Stock, plus the number of shares of Common Stock that are automatically added on January 1 of each year for a period of up to ten years, commencing on the first
January 1 following the IPO Date and ending on (and including) January 1, 2024, in an amount equal to the lesser of (i) 2.0% of the total number of shares of Capital Stock outstanding on December 31 of the preceding fiscal year,
and (ii) 200,000 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any fiscal year to provide that there will be no January 1 increase in the share reserve for such fiscal year or that the
increase in the share reserve for such fiscal year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. 

(b) If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan.  
 (c) The stock purchasable
under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market.  

4. GRANT OF PURCHASE RIGHTS; OFFERING. 

(a) The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering
(consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate, and will comply 

  
 2 

 
with the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering shall be
incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document
comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive.

 (b) If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms
delivered to the Company: (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have
identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.

 (c) The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on
the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i) that Offering will terminate immediately as of that
first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period.  

5. ELIGIBILITY. 
 (a)
Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section 2(b), to Employees of a Related Corporation. Except as provided in Section 5(b), an Employee will not be eligible
to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in
no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such
Employee’s customary employment with the Company or the Related Corporation is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the
Code.  
 (b) The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee
will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be
deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that: 

  
 3 

 (i) the date on which such Purchase Right is granted will be the “Offering Date”
of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; 
 (ii) the
period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and 

(iii) the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of
the Offering, he or she will not receive any Purchase Right under that Offering. 
 (c) No Employee will be eligible for the
grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related
Corporation. For purposes of this Section 5(c), the rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and
options will be treated as stock owned by such Employee. 
 (d) As specified by Section 423(b)(8) of the Code, an Eligible
Employee may be granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee’s rights to
purchase stock of the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of
their respective Offering Dates) for each calendar year in which such rights are outstanding at any time. 
 (e) Officers of
the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are
highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate. 
 6.
PURCHASE RIGHTS; PURCHASE PRICE. 
 (a) On each Offering Date, each
Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the
Board, but in either case not exceeding 15% of such Employee’s earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and
ends on the date stated in the Offering, which date will be no later than the end of the Offering. 
 (b) The Board will establish one
or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. 

  
 4 

 (c) In connection with each Offering made under the Plan, the Board may specify (i) a
maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such
Offering and/or (iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase
Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant’s accumulated Contributions) allocation of the shares of Common Stock
available will be made in as nearly a uniform manner as will be practicable and equitable. 
 (d) The purchase price of shares
of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of: 
 (i) an amount equal to 85% of the
Fair Market Value of the shares of Common Stock on the Offering Date; and 
 (ii) an amount equal to 85% of the Fair Market Value of
the shares of Common Stock on the applicable Purchase Date. 
 7. PARTICIPATION; WITHDRAWAL; TERMINATION.

 (a) An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by completing and
delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each
Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a
third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the
Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions. If
specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to a Purchase Date. 

(b) During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a
withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant’s Purchase Right in that Offering will immediately terminate and the Company will
distribute to such Participant all of his or her accumulated but unused Contributions and such Participant’s Purchase Right in that Offering shall thereupon terminate. A Participant’s withdrawal from that Offering will have no effect upon
his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. 

  
 5 

 (c) Purchase Rights granted pursuant to any Offering under the Plan will terminate
immediately if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or (ii) is otherwise no longer eligible to participate. The Company
will distribute to such individual all of his or her accumulated but unused Contributions.  
 (d) During a Participant’s
lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as
described in Section 10.  
 (e) Unless otherwise specified in the Offering, the Company will have no obligation to pay
interest on Contributions. 
 8. EXERCISE OF PURCHASE RIGHTS. 

(a) On each Purchase Date, each Participant’s accumulated Contributions will be applied to the purchase of shares of Common Stock,
up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering. 

(b) If any amount of accumulated Contributions remains in a Participant’s account after the purchase of shares of Common Stock and
such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant’s account for the purchase of shares of Common
Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such Offering, in which case such amount will be distributed to such Participant after the final Purchase Date, without
interest. If the amount of Contributions remaining in a Participant’s account after the purchase of shares of Common Stock is at least equal to the amount required to purchase one whole share of Common Stock on the final Purchase Date of an
Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such Offering without interest. 

(c) No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan
are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws applicable to the Plan. If on a Purchase Date
the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an
effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 6 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares
of Common Stock are not registered and the Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest.

  
 6 

 9. COVENANTS OF THE COMPANY. 

The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan
such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary
for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell
Common Stock upon exercise of such Purchase Rights. 
 10. DESIGNATION OF BENEFICIARY. 

(a) The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. 

(b) If a Participant dies, in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and/or
Contributions to the executor or administrator of the estate of the Participant. If, to the knowledge of the Company, no executor or administrator has been appointed, the Company, in its sole discretion, may deliver such shares of Common Stock
and/or Contributions to the Participant’s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. 

11. ADJUSTMENTS UPON CHANGES IN COMMON STOCK;
CORPORATE TRANSACTIONS. 
 (a) In the event of a Capitalization Adjustment, the Board will
appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities by which the share reserve is to increase
automatically each year pursuant to Section 3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv) the class(es) and number of securities
that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive.  

(b) In the event of a Corporate Transaction, then: (i) any surviving corporation or acquiring corporation (or the surviving or
acquiring corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for
outstanding Purchase Rights, or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the Participants’
accumulated Contributions will be used to purchase shares of Common Stock within ten business days prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. 

  
 7 

 12. AMENDMENT, TERMINATION OR SUSPENSION
OF THE PLAN. 
 (a) The Board may amend the Plan at any time in any respect the Board
deems necessary or advisable. However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law
or listing requirements, including any amendment that either (i) materially increases the number of shares of Common Stock available for issuance under the Plan, (ii) materially expands the class of individuals eligible to become
Participants and receive Purchase Rights, (iii) materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be purchased under the Plan, (iv) materially
extends the term of the Plan, or (v) expands the types of awards available for issuance under the Plan, but in each of (i) through (v) above only to the extent stockholder approval is required by applicable law or listing
requirements. 
 (b) The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan
while the Plan is suspended or after it is terminated. 
 (c) Any benefits, privileges, entitlements and obligations under any
outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase
Rights were granted, (ii) as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance
issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain or
maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies
with the requirements of Section 423 of the Code. 
 13. EFFECTIVE DATE OF PLAN.

 The Plan will become effective immediately prior to and contingent upon the IPO Date. No Purchase Rights will be exercised unless and
until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a) above, materially amended) by the Board. 

14. MISCELLANEOUS PROVISIONS. 

(a) Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. 

(b) A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant’s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). 

  
 8 

 (c) The Plan and Offering do not constitute an employment contract. Nothing in the Plan or
in the Offering will in any way alter the at will nature of a Participant’s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation,
or on the part of the Company or a Related Corporation to continue the employment of a Participant. 
 (d) The provisions of the Plan
will be governed by the laws of the State of California without resort to that state’s conflicts of laws rules. 
 15. DEFINITIONS.

 As used in the Plan, the following definitions will apply to the capitalized terms indicated below: 

(a) “Board” means the Board of Directors of the Company. 

(b) “Capital Stock” means each and every class of common stock of the Company,
regardless of the number of votes per share. 
 (c) “Capitalization
Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of
consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of
shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).
Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. 

(d) “Code” means the Internal Revenue Code of 1986, as amended, including any
applicable regulations and guidance thereunder. 
 (e)
“Committee” means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c). 

(f) “Common Stock” means, as of the IPO Date, the common stock of the Company. 

(g) “Company” means Virobay, Inc., a Delaware corporation. 

(h) “Contributions” means the payroll deductions and other additional payments specifically
provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant
has not already had the maximum permitted amount withheld during the Offering through payroll deductions. 

  
 9 

 (i) “Corporate Transaction” means the
consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: 

(i) a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated
assets of the Company and its Subsidiaries; 
 (ii) a sale or other disposition of at least 90% of the outstanding securities of the
Company; 
 (iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or 

(iv) a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common
Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or
otherwise. 
 (j) “Director” means a member of the Board. 

(k) “Eligible Employee” means an Employee who meets the requirements set forth in
the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. 

(l) “Employee” means any person, including an Officer or Director, who is
“employed” for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an
“Employee” for purposes of the Plan.  
 (m) “Employee Stock Purchase
Plan” means a plan that grants Purchase Rights intended to be options issued under an “employee stock purchase plan,” as that term is defined in Section 423(b) of the Code. 

(n) “Exchange Act” means the Securities Exchange Act of 1934, as amended and the
rules and regulations promulgated thereunder. 
 (o) “Fair Market Value” means, as of any date,
the value of the Common Stock determined as follows: 
 (i) If the Common Stock is listed on any established stock exchange or traded
on any established market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on
the date of determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing sales price on the last preceding date for which such quotation exists. 

  
 10 

 (ii) In the absence of such markets for the Common Stock, the Fair Market Value will be
determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Sections 409A of the Code. 

(iii) Notwithstanding the foregoing, for any Offering that commences on the IPO Date, the Fair Market Value of the shares of Common
Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company’s initial public offering as specified in the final prospectus for that initial public offering. 

(p) “IPO Date” means the date of the underwriting agreement between the Company and
the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. 

(q) “Offering” means the grant to Eligible Employees of Purchase Rights, with the
exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the “Offering Document” approved by the Board for
that Offering. 
 (r) “Offering Date” means a date selected by the Board for an Offering to
commence. 
 (s) “Officer” means a person who is an officer of the Company or a
Related Corporation within the meaning of Section 16 of the Exchange Act. 
 (t)
“Participant” means an Eligible Employee who holds an outstanding Purchase Right. 
 (u)
“Plan” means this Virobay, Inc. 2014 Employee Stock Purchase Plan. 
 (v)
“Purchase Date” means one or more dates during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance
with such Offering. 
 (w) “Purchase Period” means a period of time
specified within an Offering, generally beginning on the Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. 

(x) “Purchase Right” means an option to purchase shares of Common Stock granted pursuant to the Plan. 

(y) “Related Corporation” means any “parent corporation” or
“subsidiary corporation” of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. 

(z) “Securities Act” means the Securities Act of 1933, as amended. 

(aa) “Trading Day” means any day on which the exchange(s) or market(s) on which
shares of Common Stock are listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. 

  
 11Prepared by R.R. Donnelley Financial -- EX-10.12

 Exhibit 10.12 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 EXECUTION VERSION 

DEVELOPMENT AND LICENSE AGREEMENT 

This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”)
is entered into as of January 4, 2012 (the “Effective Date”) by and between VIROBAY INC., a Delaware corporation with its principal place of business at 1490 O’Brien Drive, Suite G,
Menlo Park, CA 94025, USA (“Virobay”), and LEO PHARMA A/S, a Danish private limited company with its principal place of business at 55, Industriparken, 2750 Ballerup, Denmark (“LEO”). Virobay
and LEO are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 

WHEREAS, Virobay is developing its proprietary small molecule Cathepsin S inhibitor referred to as VBY-891 for the
treatment of psoriasis and other indications; 
 WHEREAS, LEO possesses substantial resources and
expertise in the development, marketing, and commercialization of pharmaceutical products in the field of dermatology; and 

WHEREAS, Virobay desires to grant LEO an exclusive license, and LEO desires to obtain a license,
to develop and commercialize products containing VBY-891, or potentially other compounds, for treating certain dermatological conditions and potentially other indications, and the Parties desire that Virobay conduct certain early clinical
development of VBY-891, all in accordance with the terms and conditions set forth herein. 
 NOW,
THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS

 1.1 “Acquiror” has the meaning set forth in Section 15.6. 

1.2 “Affiliate” means, with respect to a particular Party or other entity, a person, corporation, partnership, or
other entity that controls, is controlled by or is under common control with such Party or other entity. For the purposes of this definition, the word “control” (including, with correlative meaning, the terms “controlled by” or
“under common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty
percent (50%) or more of the voting stock of such entity, or by contract or otherwise. 
 1.3 “Bankruptcy Code”
has the meaning set forth in Section 13.3(b)(i). 
 1.4 “Business Day” means a day other than Saturday, Sunday or
any day that banks in Copenhagen, Denmark or San Francisco, California, U.S. are required or permitted to be closed. 
 1.5
[* * *] means the [* * *] Agreement between Virobay and  

  
 1 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 [* * *], by and through its [* * *] dated [* * *], as
amended as of the [* * *]. 
 1.6 “Claims” has the meaning set forth in Section 11.1. 

1.7 “Clinical Trial” means any human clinical trial of a Compound or Licensed Product. 

1.8 “Commercialization” means the marketing, promotion, sale and/or distribution of a Licensed Product in the
Territory. Commercialization shall include commercial activities conducted in preparation for Licensed Product launch. “Commercialize” has a correlative meaning. 

1.9 “Commercially Reasonable Efforts” means, with respect to (a) LEO’s obligations under this Agreement to
Develop or Commercialize a Licensed Product in the Field, the carrying out of such obligations or tasks with a level of efforts and resources consistent with the commercially reasonable practices of the pharmaceutical industry (including
consideration of potentially competitive products) for the development or commercialization of a similarly situated pharmaceutical product as such Licensed Product with a high priority level and at a similar stage of development or
commercialization; or (b) Virobay’s obligations under this Agreement to Develop and Manufacture a Licensed Product in the Field, the carrying out of such obligations or tasks with a level of efforts and resources consistent with the
commercially reasonable practices of the pharmaceutical industry for the development and manufacture of a similarly situated pharmaceutical product as such Licensed Product with a high priority level as a product at a similar stage of development or
commercialization. Commercially Reasonable Efforts requires that a Party: (a) promptly assign responsibility for such obligations or tasks to specific employee(s) who are held accountable for progress and monitor such progress on an on-going
basis, (b) set and consistently seek to achieve specific and meaningful objectives for carrying out such obligations, and (c) consistently make and implement decisions and allocate resources designed to advance progress with respect to
such objectives. 
 1.10 “Compound” means: (a) initially, the compound referred to by Virobay as VBY-891, as
set forth in Exhibit A (“VBY-891”); or (b) any compound that [* * *] (or another Compound) pursuant to Section 4.5, and in each case (a) and (b) any [* * *] form of such
compound. A Compound that is replaced pursuant to Section 4.5 shall no longer be a Compound and in any event shall thereafter not be further developed by a Party during the Term. 

1.11 “Confidential Information” of a Party means any and all Information of such Party that is disclosed to the other
Party under this Agreement, whether in oral, written, graphic, or electronic form. All Information disclosed by either Party pursuant to the Confidentiality Agreement between the Parties dated October 18, 2010 (the “Confidentiality
Agreement”) shall be deemed to be such Party’s Confidential Information disclosed hereunder. 
 1.12
“Control” means, with respect to any material, Information, or intellectual property right, that a Party (a) owns or (b) has a license (other than a license granted to such

  
 2 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Party under this Agreement) to such material, Information, or intellectual property right and, in each case, has the ability to grant to the other Party access, a license, or a sublicense (as
applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any then-existing agreement or other legally enforceable arrangement with any Third Party. 

1.13 “cGMP” or “Current Good Manufacturing Practices” means the then-current standards for the
manufacture of pharmaceutical products, pursuant to (a) Eudralex Volume 4 part I: EU Guidelines to Good Manufacturing Practice for Human and Veterinary Use; (b) Code of Federal Regulations 21, Part 210 and 211; (c) any additional
comparable laws or regulations applicable in the Territory to the manufacture and testing of pharmaceutical products promulgated by other Regulatory Authorities; and (d) all additional Regulatory Authority documents or regulations that replace,
amend, modify, supplement, supplant or complement any of the foregoing. 
 1.14 “Dermatology Field” means the
diagnosis, treatment and prevention of those Indications that fall within the scope of [* * *] but excluding (a) any [* * *] and (b) any and all of the following: [* * *]. 

1.15 “Development” means all activities that relate to obtaining, maintaining or expanding Regulatory Approval of a
Licensed Product. This includes: (i) preclinical testing, toxicology, and Clinical Trials; and (ii) preparation, submission, review, and development of data or information for the purpose of submission to a Governmental Authority to
obtain, maintain and/or expand Regulatory Approval of a Licensed Product, and outside counsel, regulatory, and legal services related thereto; provided, however, that Development shall exclude Commercialization and the building of commercial
inventory of a Licensed Product. “Develop” has a correlative meaning. 
 1.16 “Development Plan”
has the meaning set forth in Section 4.3(a). 
 1.17 “Development Program” has the meaning set forth in Section
4.3(a). 
 1.18 “Development Transition” means the completion by Virobay of all activities under the Development
Plan, completion of technology transfer to LEO and assignment of the IND for the Compound in the U.S. to LEO, as confirmed by the JSC pursuant to Section 4.4. 

1.19 “Dollar” means a U.S. dollar, and “$” shall be interpreted accordingly. 

1.20 “EMA” means the European Medicines Agency or any successor entity. 

1.21 “EU” or “European Union” means the European Union member states as then constituted. As of the
Effective Date, the European Union member states are Austria, Belgium, 

  
 3 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania,
Slovakia, Slovenia, Spain, Sweden, and United Kingdom. 
 1.22 “Executive Officer” means, with respect to Virobay,
its Chief Executive Officer, and with respect to LEO, its Senior Vice President, Global Development. 
 1.23 “Ex-US
Patents” means those national phase Patents in the Key Ex-US Counties that correspond to the published PCT application listed on Exhibit B hereto. 

1.24 “FD&C Act” means the U.S. Federal Food, Drug and Cosmetic Act, as amended. 

1.25 “FDA” means the U.S. Food and Drug Administration or any successor entity. 

1.26 “Field” means the diagnosis, treatment and prevention of the following Indications: (a) psoriasis (including
[* * *] psoriasis and psoriatic [* * *] (it being understood that all forms of psoriasis are considered a single Indication) [* * *]; and (b) up to [* * *] Indications in the
Dermatology Field added by LEO pursuant to Section 2.1(e). 
 1.27 “First Commercial Sale” means, with respect
to a Licensed Product, the first sale on a commercial basis to a Third Party of such Licensed Product in a given regulatory jurisdiction after Regulatory Approval has been obtained in such jurisdiction. 

1.28 “FTE” means the equivalent of a full-time professional individual’s work, at [* * *] hours
per year, [* * *], for a twelve (12)-month period, performing activities under the Development Plan. In the case that any full time personnel of Virobay [* * *], then [* * *]. FTE efforts shall
[* * *] and shall not [* * *]. Virobay shall track FTEs using its standard practice and normal systems and methodologies, all as accounted for and consistently applied according to U.S. generally accepted accounting
principles (“GAAP”). 
 1.29 “FTE Rate” means the rate of FTE costs incurred by Virobay, which for
the purpose of this Agreement shall be [* * *] per FTE. 
 1.30 “Generic Product” means,
with respect to a Licensed Product in a particular regulatory jurisdiction, any pharmaceutical product that (a) contains the [* * *] as such Licensed Product in the [* * *] as such Licensed Product and for the
[* * *] as such Licensed Product and is [* * *] in such jurisdiction ([* * *] for which such Licensed Product 

  
 4 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
[* * *] from the applicable [* * *] in such jurisdiction) on an [* * *] in a manner that [* * *] in connection with the
[* * *] for the Licensed Product [* * *] and (b) [* * *] with respect to such Licensed Product; and (c) [* * *] in such jurisdiction [* * *] Licensed
Product. For purposes of this definition, [* * *] means, [* * *] as determined by [* * *] applying the definition of [* * *] set forth in the [* * *] such
equivalent determination by the applicable [* * *] as is [* * *] under applicable Laws [* * *] in the absence of [* * *] under applicable Laws. 

1.31 “GCP” or “Good Clinical Practices” means the then-current standards, practices and procedures
promulgated or endorsed by the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements imposed by the FDA and comparable regulatory
standards, practices and procedures promulgated by the EMA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time, including applicable quality guidelines promulgated under the ICH. 

1.32 “GLP” or “Good Laboratory Practices” means the then-current good laboratory practice standards
promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable regulatory standards promulgated by the EMA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time, including applicable
quality guidelines promulgated under the ICH. 
 1.33 “Governmental Authority” means any multi-national, federal,
state, local, municipal, provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

1.34 “ICH” means International Conference on Harmonisation. 

1.35 “IND” means (a) an Investigational New Drug Application as defined in the FD&C Act and applicable
regulations promulgated thereunder by the FDA, or (b) the equivalent application to the equivalent agency in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product
in humans in such jurisdiction. 
 1.36 “Indemnified Party” has the meaning set forth in Section 11.3. 

1.37 “Indemnifying Party” has the meaning set forth in Section 11.3. 

  
 5 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 1.38 “Indication” means a separately defined, well-categorized class
of human disease or condition for which a separate MAA or extension or supplement may be filed with a Regulatory Authority other than for an extended release or similar re-formulation of a product with respect to which an MAA has been previously
approved. 
 1.39 “Information” means any data, results, technology, business or financial information or
information of any type whatsoever, in any tangible or intangible form, including know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulations, formulae, materials or compositions of
matter of any type or kind (patentable or otherwise), software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, clinical test data and data resulting from non-clinical
studies), CMC information, stability data and other study data and procedures. 
 1.40 “Joint Inventions” has the
meaning set forth in Section 9.1. 
 1.41 “Joint Patents” has the meaning set forth in Section 9.1. 

1.42 “Joint Steering Committee” or “JSC” means the committee formed by the Parties as described in
Section 3.2. 
 1.43 “Key Ex-US Countries” means [* * *]. 

1.44 “Laws” means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law
of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 

1.45 “LEO Indemnitees” has the meaning set forth in Section 11.1. 

1.46 “LEO Know-How” means all Information Controlled by LEO or its Affiliates as of the Effective Date or during the
Term (other than as a result of a license from Virobay) that is necessary or reasonably useful for the Development, Manufacture or Commercialization of Compounds or Licensed Products in the Field. For clarity, LEO Know-How excludes Information
contained within the LEO Patents, and the use of “Affiliate” in this definition shall exclude any Third Party that becomes an Affiliate after the Effective Date due to an acquisition by such Third Party or its Affiliate of LEO, subject to
the terms of Section 15.6.  
 1.47 “LEO Patent” means any Patent (other than a Joint Patent) that
(a) is Controlled by LEO or its Affiliates as of the Effective Date or at any time during the Term (other than as a result of a license or assignment from Virobay), and (b) claims the composition of matter, manufacture or use of one or
more Compounds or Licensed Products or that would otherwise be infringed, absent a license, by the manufacture, use or sale of any Compound or Licensed Product. For clarity, the use of “Affiliate” in this definition shall exclude any Third
Party that becomes an Affiliate after the Effective Date due to an acquisition by such Third Party or its Affiliate of LEO, subject to the terms of Section 15.6. 

1.48 “LEO Technology” means the LEO Know-How, LEO Patents and LEO’s interest in the Joint Patents. 

  
 6 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 1.49 “Licensed Field” means the diagnosis, treatment and prevention
of any and all Indications, but [* * *]. For the avoidance of doubt, the Licensed Field includes the Dermatology Field. 

1.50 “Licensed Product” means any pharmaceutical product, including all forms, presentations, doses and formulations,
containing a Compound alone or in combination with other therapeutically active ingredients. 
 1.51 “Lien” means a
claim, mortgage, deed of trust, levy, charge, pledge, security interest, or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against the Ex-US Patents. 

1.52 “Manufacture” means all activities related to the manufacturing of a pharmaceutical product, or any ingredient
thereof, including test method development and stability testing, formulation, process development, manufacturing scale-up, manufacturing any Compound or Licensed Product in bulk or finished form for Development, manufacturing finished Licensed
Product for Commercialization, packaging, in-process and finished Licensed Product testing, release of Licensed Product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of Licensed Product,
and regulatory activities related to any of the foregoing. “Manufacturing” has a correlative meaning. 
 1.53
“Manufacturing Cost” means (i) with respect to a Compound or Licensed Product that is Manufactured by a Third Party, the purchase price approved in advance by the JSC and actually paid by Virobay or its Affiliate to such Third
Party for such Compound or Licensed Product, and (ii) with respect to a Compound or Licensed Product that is Manufactured directly by Virobay or its Affiliate, the cost of direct labor and direct materials, product testing costs incurred in
connection with Manufacturing, start-up and on-going validation costs directly associated with the Manufacture of the Licensed Product or Compound, facility costs including depreciation, and overhead, such calculation being based upon accepted
industry standards and GAAP. 
 1.54 “Marketing Authorization Application” or “MAA” means an
application to the appropriate Regulatory Authority for approval to market a Licensed Product (but excluding Pricing Approval) in any particular jurisdiction, including an NDA in the U.S. 

1.55 “MHLW” means the Japanese Ministry of Health, Labour and Welfare or any successor entity. 

1.56 “NDA” means a New Drug Application, as defined in the FD&C Act, as amended, and applicable regulations
promulgated thereunder by the FDA. 
 1.57 “Net Sales” means, with respect to any Licensed Product, the gross
amounts invoiced and/or received by LEO, its Affiliates and their respective sublicensees for sales of such Licensed Product to unaffiliated Third Parties, less the following deductions provided to unaffiliated entities and actually allowed and
taken with respect to such sales: 
 (a) reasonable cash, trade or quantity discounts, charge-back payments, and rebates actually
granted to trade customers, managed health care organizations, pharmaceutical benefit managers, group purchasing organizations and national, state, or local government; 

  
 7 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) credits, rebates or allowances actually allowed upon prompt payment or on account
of claims, damaged goods, rejections or returns of such Licensed Product, including in connection with recalls, and the actual amount of any write-offs for bad debt (provided that an amount subsequently recovered will be treated as Net Sales); 

(c) freight, postage, shipping, transportation and insurance charges, in each case actually allowed or paid for delivery of such
Licensed Product; and 
 (d) taxes (other than income taxes), duties, tariffs, mandated contribution or other governmental charges
levied on the sale of such Licensed Product, including VAT, excise taxes and sales taxes. 
 Notwithstanding the foregoing, amounts received
or invoiced by LEO, its Affiliates, or their respective sublicensees for the sale of such Licensed Product among LEO, its Affiliates or their respective sublicensees for resale shall not be included in the computation of Net Sales hereunder, but the
final sale of such Licensed Product by LEO, its Affiliate or one of their respective sublicensees to an unaffiliated Third Party shall be included in Net Sales. For purposes of determining Net Sales, a Licensed Product shall be deemed to be sold
when invoiced. Net Sales shall be accounted for in accordance with standard LEO practices for operation by LEO, its Affiliates or sublicensees, as practiced in the relevant country in the Territory. 

Notwithstanding the foregoing, “Net Sales” shall not include any amounts invoiced for sales of Licensed Products supplied for use in
Clinical Trials of Licensed Products in the Field. 
 If a Licensed Product contains a Compound in combination with any other clinically
active ingredient(s) that is not a Compound, whether packaged together or in the same therapeutic formulation, in any country, Net Sales for such combination product in such country shall be calculated as follows: 

(i) If the Compound and other clinically active ingredient(s) each are sold separately in such country, Net Sales will be calculated
by multiplying the total Net Sales (as described above) of such combination product by the fraction A/(A+B), where A is the public or list price in such country of the Compound sold separately in the same formulation and dosage, and B is the sum of
the public or list price in such country of such other clinically active ingredient(s) sold separately in the same formulation and dosage, during the applicable calendar year. 

(ii) If the Compound is sold independently of the other clinically active ingredient(s) therein in such country, but the public or
list price of such other clinically active ingredient(s) cannot be determined, Net Sales will be calculated by multiplying the total Net Sales (as described above) of such combination product by the fraction A/C, where A is the public or list price
in such country of such Compound sold independently and C is the public or list price in such country of the entire combination product. 

(iii) If the other clinically active ingredient(s) are sold independently of the Compound therein in such country, but the public or
list price of such Compound cannot be determined, Net Sales will be calculated by multiplying the total Net Sales (as described above) of such combination product by the fraction [1-(B/C)], where B is the public or list price in such country of such
other clinically active ingredient(s) and C is the public or list price in such country of the entire combination product. 

  
 8 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 1.58 “Pain Field” means the [* * *] For clarity,
[* * *] included in the [* * *] shall be deemed not to be in the [* * *] where the [* * *] for such [* * *] is not directed to [* * *] in the
[* * *] 
 1.59 “Patents” means (a) pending patent applications, issued patents, utility
models and designs; (b) reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing; and
(c) extensions, renewals or restorations of any of the foregoing by existing or future extension, renewal or restoration mechanisms, including supplementary protection certificates or the equivalent thereof. 

1.60 “Permitted Liens” are: 

(a) Liens existing on the Effective Date; 

(b) Liens for taxes, fees, assessments or other government charges or levies; 

(c) banker’s Liens, rights of setoff and Liens in favor of financial institutions incurred or made in connection with letters of
credit issued in favor of Virobay; 
 (d) statutory Liens securing claims or demands of materialmen, mechanics, carriers,
warehousemen, landlords and other Persons imposed without action of such parties, provided they have no priority over LEO’s Lien; and 

(e) licenses of other products claimed by the Ex-US Patents as provided in Section 2.6(d) hereof. 

1.61 “Phase 1b/2a Clinical Trial” means the phase 1b/2a Clinical Trial of a Licensed Product as described in the
Development Plan. 
 1.62 “Phase 2 Clinical Trial” means a Clinical Trial of a Licensed Product in the Field, the
principal purpose of which is to evaluate the effectiveness of such Product in the target patient population, as further defined in 21 C.F.R. 312.21(b) for the U.S., as amended from time to time, or the corresponding foreign regulations 

1.63 “Phase 2b Clinical Trial” means a twelve (12)-week proof of concept phase 2b Clinical Trial of a Licensed Product
in the Field to determine initial efficacy and dose range and/or regimen finding before embarking on a Phase 3 Clinical Trial, as further defined in 21 C.F.R. 312.21(b) for the U.S., as amended from time to time, or the corresponding foreign
regulations. 

  
 9 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 1.64 “Phase 3 Clinical Trial” means a pivotal Clinical Trial of a
Licensed Product (whether or not denominated a “Phase 3” Clinical Trial under applicable regulations) in the Field with a defined dose or a set of defined doses of such Licensed Product designed to ascertain efficacy and safety of such
Licensed Product for the purpose of enabling the preparation and submission of an MAA to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. 312.21(c) for the U.S., as amended from time to time, or the
corresponding foreign regulations. 
 1.65 “Pricing Approval” means such governmental approval, agreement,
determination or decision establishing prices for a Licensed Product that can be charged and/or reimbursed in regulatory jurisdictions where the applicable Governmental Authorities approve or determine the price and/or reimbursement of
pharmaceutical products. 
 1.66 “Product Infringement” has the meaning set forth in Section 9.4(a). 

1.67 “Product Marks” has the meaning set forth in Section 9.11. 

1.68 “Regulatory Approval” means all approvals, including Pricing Approvals if applicable, necessary for the
commercial sale of a Licensed Product in the Field in a given country or regulatory jurisdiction 
 1.69 “Regulatory
Authority” means, in a particular country or jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval in such country or jurisdiction. 

1.70 “Regulatory Materials” means regulatory applications, submissions, notifications, communications, correspondence,
registrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise Commercialize a Licensed Product in a particular country
or jurisdiction. 
 1.71 “Restricted Compound” means any compound that is disclosed or claimed in any Virobay Patent
and that specifically inhibits [* * *], as shown by [* * *] that is [* * *] for a [* * *] and [* * *], including the [* * *] of any of the
foregoing compounds. 
 1.72 “Royalty Term” has the meaning set forth in Section 8.5(b). 

1.73 “Section 365(n)” has the meaning set forth in Section 13.3(b)(i). 

1.74 “Sole Inventions” has the meaning set forth in Section 9.1. 

1.75 “Sublicense Revenue” means all upfront consideration and milestone payments that are received by LEO from a
sublicensee pursuant to an agreement in which the sublicensee 

  
 10 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
receives a sublicense in Asia under the rights granted to LEO under Section 2.1(a), but specifically excluding payments to the extent made: (i) in consideration of the issuance of
rights to other products of LEO; (ii) with respect to research, development or commercialization activities undertaken by LEO; (iii) for capital expenditures; (iv) to reimburse LEO for amounts paid or costs incurred by or on behalf of
LEO in connection with patent prosecution, maintenance, enforcement, or defense; (v) as a bona fide loan or as a distribution of a patent enforcement award; or (vi) with respect to the supply of goods and/or services by or on behalf of
LEO. If, in the same agreement in which LEO grants a sublicense in Asia under the Virobay Technology, LEO also grants a license under other intellectual property and/or grants a sublicense under the Virobay Technology in other countries, then LEO
shall be permitted to (a) reasonably allocate any payments received thereunder among the various licensed intellectual properties and/or licensed territories, and (b) exclude from Sublicense Revenue the portions of any such payments that
are reasonably allocated to intellectual property other than the Virobay Technology and/or to territories outside Asia. 
 1.76
“Term” has the meaning set forth in Section 13.1. 
 1.77 “Territory” means all countries of the
world. 
 1.78 “Third Party” means any entity other than Virobay or LEO or an Affiliate of either of them. 

1.79 “U.S.” means the United States of America, including all possessions and territories thereof. 

1.80 “U.S. Virobay Bankruptcy” has the meaning set forth in Section 13.3(b)(i). 

1.81 “Valid Claim” means a claim of an issued and unexpired patent (as may be extended through supplementary
protection certificate or patent term extension or the like) included within the Virobay Patents, to the extent such claim has not been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent
jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue,
re-examination or disclaimer or otherwise. 
 1.82 “Virobay Indemnitees” has the meaning set forth in Section
11.2. 
 1.83 “Virobay Know-How” means all Information Controlled by Virobay or its Affiliates as of the Effective
Date or during the Term (other than as a result of a license from LEO) that is necessary or reasonably useful for the Development, manufacture or Commercialization of Compounds or Licensed Products in the Field. For clarity, Virobay Know-How
excludes Information contained within the Virobay Patents, and the use of “Affiliate” in this definition shall exclude any Third Party that becomes an Affiliate after the Effective Date due to an acquisition by such Third Party or its
Affiliate of Virobay, subject to the terms of Section 15.6. 

  
 11 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 1.84 “Virobay Patent” means any Patent (other than a Joint Patent)
that (a) is Controlled by Virobay or its Affiliates as of the Effective Date or at any time during the Term (other than as a result of a license from LEO), and (b) claims the composition of matter, manufacture or use in the Field of one or
more Compounds or that would otherwise be infringed, absent a license, by the manufacture, use in the Field or sale of any Compound. For clarity, the use of “Affiliate” in this definition shall exclude any Third Party that becomes an
Affiliate after the Effective Date due to an acquisition by such Third Party or its Affiliate of Virobay, subject to the terms of Section 15.6. The list of Virobay Patents as of the Effective Date is attached hereto as Exhibit B. 

1.85 “Virobay Technology” means the Virobay Know-How, Virobay Patents and Virobay’s interest in the Joint
Patents. 
 ARTICLE 2 

LICENSES, EXCLUSIVITY AND RELATED RIGHTS 

2.1 License to LEO under Virobay Technology. 

(a) License to LEO. Subject to the terms and conditions of this Agreement, Virobay hereby grants LEO an exclusive (even as to Virobay
except as provided in Section 2.1(b) below), royalty-bearing license, with the right to sublicense through multiple tiers, under the Virobay Technology to research, Develop, make, have made, use, sell, offer for sale, import, export and
otherwise Manufacture and Commercialize Compounds and Licensed Products in the Licensed Field in the Territory; provided, however, that LEO may practice such license outside the Field only pursuant to an agreement between the Parties under Section
2.1(f). 
 (b) Virobay Retained Rights. Notwithstanding the rights granted to LEO in Section 2.1(a) and without limiting the
generality of Section 2.5, Virobay retains the following: (i) the right to practice the Virobay Technology in the Territory to exercise its rights or to fulfill its obligations under this Agreement, including the Manufacture and
Development of Compounds and Licensed Products under the Development Plan; and (ii) subject to Section 2.3, the right to practice and license the Virobay Technology outside the scope of the license granted to LEO in Section 2.1(a). 

(c) Sublicenses. In each sublicense that LEO grants hereunder, LEO shall require that, upon a termination of such sublicense, the
sublicensee must promptly transfer and assign to LEO all Regulatory Materials, Regulatory Approvals, and related data and Information relating to the Licensed Products and Compounds that are owned or controlled by such sublicensee (such that LEO
will be able to, pursuant to Section 13.4(b), transfer and assign to Virobay all such Regulatory Materials, Regulatory Approvals, and related data and Information upon termination of this Agreement). In addition, LEO shall ensure that any
sublicense that LEO grants hereunder explicitly states that such sublicense will immediately terminate upon termination of this Agreement. Any sublicense that LEO grants hereunder shall be consistent with the terms and conditions of this Agreement
and shall provide that the sublicensee shall be bound by and subject to all applicable terms and conditions of this Agreement in the same manner and to the same extent as LEO is bound thereby. LEO shall remain primarily responsible

  
 12 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
for all of its sublicensees’ activities and any and all failures by its sublicensees to comply with the applicable terms of this Agreement. LEO shall, within [* * *] days
after granting a Third Party a sublicense of the right to Commercialize the Licensed Products under Section 2.1(a) above, notify Virobay of the grant of such license or sublicense, summarizing the license scope and territory. 

(d) Additional Permitted Sales. 

(i) The Parties understand and acknowledge that a Regulatory Approval for a Licensed Product in an approved Indication in the Field
may authorize additional labeling or label claims that [* * *] associated with such approved Indication. The Parties agree that marketing, promotion and sale of a Licensed Product for such [* * *] shall not be
prohibited or deemed a breach of this Agreement by LEO, or a use of the Virobay Technology by LEO outside the applicable Indications in the Field. For example, LEO shall have the right, to the extent permitted under applicable Laws, in connection
with its Development and Commercialization of Licensed Products in an Indication in the Field, to publish or otherwise publicly disclose any [* * *] with an approved Indication in the Field if such [* * *] are
included in the label for a Licensed Product or are otherwise the subject of published medical science data or information, whether or not included in the label for the Licensed Product. Notwithstanding anything to the contrary herein, nothing
herein shall permit LEO to market or promote a Licensed Product in [* * *] 
 (ii) In addition, despite LEO’s
promotion of Licensed Products solely in the applicable Indications in the Field, and despite the fact that LEO will seek Regulatory Approval for Licensed Products solely in the applicable Indications in the Field, customers or other Third Parties
may purchase a Licensed Product (that has received Regulatory Approval for and is sold for use in a particular Indication(s)) and use such Licensed Product off-label outside the applicable Indications in the Field (including in the Pain Field). Any
such sales resulting in off-label uses shall not be deemed (A) a breach of this Agreement by LEO, (B) a use of the Virobay Technology by LEO outside the applicable Indications in the Field or (C) marketing or promotion by LEO
[* * *]. 
 (e) Field Indications. Following the Effective Date, LEO shall have the right to nominate, by written
notification to Virobay from time to time, up to [* * *] additional Indications in the Dermatology Field to be included in the Field. In addition, after LEO nominates (and Virobay approves pursuant to the process described below)
all [* * *] additional Indications, LEO may nominate additional Indications in the Dermatology Field as replacements, on a one-for-one basis, for Indications that are then included in the Field (it being understood that LEO and its
Sublicensees will cease all development and/or commercialization efforts with respect to the Licensed Product in the replaced Indication). Any new Indication, whether proposed as part of the initial [* * *] additional Indications or
as a replacement Indication, shall be subject to written approval by Virobay; provided, however, that Virobay shall only be permitted to withhold such approval if the proposed Indication does not fall within the Dermatology Field or Virobay has
reasonable concerns that permitting LEO to exploit its license in Section 2.1(a) with respect to the proposed Indication would be likely to have a material negative impact on Virobay’s other pre-clinical or clinical development programs
outside the 

  
 13 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Dermatology Field then being actively conducted. Any rejection by Virobay shall include a description of the grounds on which Virobay bases its rejection. Upon either Party’s request, the
Parties shall discuss in good faith the proposed Indication and any concerns Virobay may have. If Virobay neither requests a discussion of the proposed Indication nor rejects the proposed Indication within [* * *] days after
receiving LEO’s notice of such proposed Indication, then Virobay shall be presumed to have accepted such proposed Indication, and the proposed Indication shall be included in the Field. 

(f) Other Indications. If LEO wishes to develop a Licensed Product for an Indication in the Licensed Field, where such Indication is
(i) outside the Field and (ii) not covered by Section 2.1(e), LEO shall notify Virobay in writing. Upon Virobay’s receipt of such notice, the Parties shall discuss and negotiate in good faith the financial and other terms under
which LEO would be permitted to exploit the license in Section 2.1(a) for the applicable Indication. If the Parties reach mutual agreement on such terms, the Parties shall execute a written amendment to this Agreement to include such agreed
terms. 
 (g) License to Virobay. Subject to the terms and conditions of this Agreement, LEO hereby grants to Virobay a
non-exclusive, fully-paid, royalty-free license, without the right to grant sublicenses (except to Affiliates and subcontractors permitted under Section 4.10), under the LEO Technology during the Term prior to Development Transition, for the
sole purpose of conducting any and all activities assigned to Virobay under the Development Plan. 
 2.2 Negative Covenants. 

(a) The license granted to LEO in Section 2.1(a) is limited to the Licensed Field, which does not include any Indications in the
Pain Field. Subject to Section 2.1(d), LEO covenants that it will not, and will not permit any of its Affiliates or sublicensees to, develop a Licensed Product in the Pain Field. 

(b) Virobay covenants that it will not, and will not permit any of its Affiliates or licensees to, use or practice any LEO Technology
outside the scope of the licenses granted to it under Section 2.1(g). 
 (c) LEO covenants that it will not, and will not permit any
of its Affiliates, licensees, or sublicensees to, use or practice any Virobay Technology outside the scope of the licenses granted to it under Section 2.1(a). 

2.3 [* * *]. Virobay covenants that it (a) [* * *]; and (b) [* * *],
except in each case ((a) or (b)) in accordance with this Section 2.3. For clarity, Virobay shall be permitted to [* * *], subject to the terms of this Section 2.3. In the event that Virobay [* * *],

  
 14 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Virobay shall [* * *]. If Virobay thereafter [* * *], it shall [* * *]. During the [* * *] days following
[* * *], the Parties shall [* * *]. If the Parties do not [* * *] within such [* * *] day period [* * *], then Virobay may [* * *]; provided,
however, that [* * *], Virobay shall not [* * *]. In any event, to the extent that Virobay [* * *], the Parties shall discuss in good faith [* * *]. 

2.4 [* * *]. Virobay understands and acknowledges that LEO is, as of the Effective Date, [* * *]. Nothing in
this Agreement is intended to or shall be deemed to [* * *]. 
 2.5 No Implied Licenses. Except as
explicitly set forth in this Agreement, neither Party shall be deemed by estoppel or implication to have granted the other Party any license or other right to any intellectual property of such Party. 

2.6 Security Interest. 

(a) No Encumbrance. Virobay and its subsidiaries shall not create, incur, allow, or suffer any Lien on the Ex-US Patents (except
for Permitted Liens) or permit or undertake any actions that would result in any Ex-US Patent no longer being subject to the first priority security interest of LEO granted herein (except for Permitted Liens that are permitted by the terms of this
Agreement to have equal priority to LEO), or enter into any agreement, document, instrument or other arrangement with any Third Party which directly or indirectly prohibits or has the effect of prohibiting Virobay and its subsidiaries from
assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of the Ex-US Patents, except for a Third Party who is either: (i) a holder of a Permitted Lien pursuant to Section 1.60(a) or (b); or (ii) a
holder of a Permitted Lien herein pursuant to Section 1.60(c)-(e) who has provided a reasonably acceptable non-disturbance agreement for the benefit of LEO. 

  
 15 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) Grant of Security Interest. In order to secure (i) the timely satisfaction
and continuing interest in the grant of license rights in the countries of the Territory outside of the U.S. pursuant to this Agreement, (ii) all of LEO’s rights and damages in an Event of Default (as defined in Section 13.3(b)), and
(iii) Virobay’s obligations to cooperate to support LEO’s right to enforce its exclusive license in the Key Ex-U.S. Countries pursuant to Section 9.4(b), Virobay hereby grants and conveys to LEO a continuing security interest in
and lien on all of Virobay’s entire right, title and interest in and to all of the Ex-US Patents and the proceeds thereof, including, without limitation, insurance proceeds, and all supporting obligations and the security therefor or for any
right to payment (the “Collateral”). Such security interest constitutes a valid, first priority security interest in the presently existing Collateral. Virobay shall from time to time execute and deliver to LEO, at the reasonable
request of LEO, all financing statements and other documents that LEO may reasonably request, in form satisfactory to LEO, to perfect and continue the perfection of LEO’s security interests in the Collateral and in order to fully consummate all
of the transactions contemplated under this Agreement. LEO is authorized to file this Agreement (or any short-form intellectual property security agreement) with the United States Patent and Trademark Office or any other governmental agency it deems
necessary or desirable in order to secure and perfect its rights under this Agreement. 
 (c) Registration of License. LEO may
register the license or security interest under this Agreement with any patent office or similar authority in the Territory; provided that such registration shall, to the extent permitted by law, not disclose any confidential terms of this
Agreement. Virobay shall provide LEO reasonable assistance upon request for cooperation with such registration by LEO. 
 (d) Other
Virobay Licenses. In the event that Virobay grants a license to a Third Party under the Ex-US Patents (i.e., outside the scope of the rights exclusively granted to LEO under the Ex-US Patents pursuant to this Agreement), LEO hereby authorizes
Virobay to grant to such Third Party licensee a security interest in the Collateral that has the same priority as the security interest held by LEO, provided that such Third Party provides a reasonably acceptable non-disturbance agreement for the
benefit of LEO. LEO agrees to negotiate in good faith an intercreditor agreement that may be requested by any such other licensee having a security interest in the Ex-US Patents. To facilitate Virobay’s entry into such future license
agreements, LEO hereby provides, for the benefit of such other licensees, the non-disturbance agreement attached hereto as Exhibit E, and LEO agrees to work with Virobay in good faith to accommodate edits to the non-disturbance agreement
proposed by any such other licensee (it being understood that any such edits must be mutually agreed by Virobay and LEO). In addition, in the event that Virobay proposes to grant a security interest to a Third Party licensee in any of the Virobay
Patents in any country of the world other than the Key Ex-US Countries, then Virobay shall not grant such security interest without also granting LEO the same priority in such Virobay Patents as the security interest proposed to be granted to such
Third Party licensee. 
 (e) Termination. LEO’s security interest in the Collateral shall automatically terminate upon the
termination of this Agreement pursuant to Section 13.2 or for material breach by LEO pursuant to Section 13.3(a). Upon such termination of LEO’s security interest, LEO 

  
 16 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
shall promptly sign all documents reasonably requested by Virobay to document that LEO no longer has any security interest in the Collateral and shall cooperate with Virobay to record the release
and termination of such security interests. In the event LEO fails to sign and record such release and termination within [* * *] days of the date requested, LEO appoints Virobay its attorney in fact to sign and record such release
and termination and authorizes Virobay to sign and record such release and termination. Virobay’s foregoing appointment as LEO’s attorney in fact, coupled with an interest, is limited to the purposes set forth in this Section 2.6(e)
and shall be irrevocable. 
 2.7 [* * *]. 

(a) Virobay shall use reasonable efforts to [* * *]. For the avoidance of doubt, “reasonable efforts” shall
not require [* * *], and Virobay shall [* * *]. Virobay shall keep LEO reasonably informed of any [* * *]. For purposes of this Section 2.7(a), [* * *] shall include
[* * *]. 
 (b) Virobay covenants to [* * *]. Virobay shall keep LEO reasonably informed regarding
[* * *]. Virobay shall provide LEO with prompt written notice in the event that [* * *], and LEO shall have the right to [* * *]. Virobay shall not [* * *]. 

  
 17 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE 3 

GOVERNANCE 
 3.1 Joint
Steering Committee. 
 (a) Formation and Role. Within [* * *] days after the Effective Date, the Parties shall
appoint a joint steering committee (the “Joint Steering Committee” or “JSC”) to coordinate and oversee the Parties’ activities under this Agreement through the completion of Development Transition. Following
the Development Transition, the JSC shall serve solely in an advisory and information-sharing capacity, and the JSC shall disband upon the first Regulatory Approval of a Licensed Product anywhere in the Territory. The role of the JSC shall be to
manage, review and discuss Virobay’s activities with respect to the Development and Manufacture of Licensed Products and the transfer of Development responsibilities from Virobay to LEO. For that purpose and to the extent reasonably necessary,
the JSC will: 
 (i) coordinate the activities of the Parties under the Development Plan, including facilitating communications and
discussions between the Parties with respect to the Development of Compounds and Licensed Products under the Development Plan; 

(ii) review, discuss and approve any proposed amendments or revisions to the Development Plan; 

(iii) discuss and oversee Virobay’s negotiations and relationships with Third Party manufacturers of Compounds and Licensed
Products; 
 (iv) oversee the transfer of Development responsibility and Information from Virobay to LEO; 

(v) coordinate the Licensed Product Manufacturing and supply activities of the Parties, including the transfer of Manufacturing
Information and transition of Manufacturing responsibilities from Virobay to LEO pursuant to Section 7.4; 
 (vi) review, discuss
and coordinate the Parties’ scientific presentation and publication strategy relating to the Compounds and Licensed Products; 

(vii) review and facilitate discussion of any requests in relation to publications pursuant to Section 12.3; 

(viii) confirm completion of Development Transition; and 

(ix) perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement
or as determined by the Parties in writing. 
 The JSC shall have only the powers expressly assigned to it in this Section 3.1 and
elsewhere in this Agreement, and shall have no power (A) to amend, modify, or waive compliance with this Agreement; (B) to determine whether or not a breach of this Agreement has occurred; or (C) to otherwise interpret this Agreement.

 (b) Members. Each Party shall initially appoint [* * *] representatives to the JSC, each of whom will be an
officer or employee of the applicable Party having sufficient seniority within such Party to make decisions arising within the scope of the JSC’s responsibilities. The JSC may change its size from time to time by mutual consent of its members,
and each Party may replace its representatives at any time upon written notice to the 

  
 18 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
other Party. The JSC shall have a chairperson, who shall be selected by LEO. The role of the chairperson shall be to convene and preside at the meetings of the JSC, to ensure the preparation of
meeting minutes, and to resolve disputes pursuant to Section 3.1(d). 
 (c) Meetings. The JSC shall meet
[* * *], unless the Parties mutually agree in writing to a different frequency for such meetings. Either Party may also call a special meeting of the JSC (by videoconference or teleconference) by at least [* * *]
Business Days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting, and such Party shall provide the JSC no later than
[* * *] Business Days prior to the special meeting with materials reasonably adequate to enable an informed decision. No later than [* * *] Business Days prior to any meeting of the JSC, the chairperson of the JSC
shall prepare and circulate an agenda for such meeting; provided, however, that either Party may propose additional topics to be included on such agenda, either prior to or in the course of such meeting. The JSC may meet in person, by
videoconference or by teleconference, provided however, at [* * *] shall be in person unless the Parties mutually agree in writing to waive such requirement in lieu of a videoconference or teleconference. In-person JSC meetings
shall be held at locations alternately selected by Virobay and by LEO. Each Party shall bear the expense of its respective JSC members’ participation in JSC meetings. Meetings of the JSC shall be effective only if at [* * *] is
present or participating in such meeting. The chairperson of the JSC shall be responsible for preparing reasonably detailed written minutes of all JSC meetings that reflect, without limitation, all material decisions made at such meetings. The JSC
chairperson shall send draft meeting minutes to each member of the JSC for review and approval within [* * *] Business Days after each JSC meeting. Such minutes shall be deemed approved unless one or more members of the JSC objects
to the accuracy of such minutes within [* * *] Business Days of receipt. 
 (d) Decision Making. The JSC shall act
by consensus. The representatives from each Party will have, collectively, one (1) vote on behalf of that Party. The JSC shall strive to seek consensus in its actions and decision making process. If after reasonable discussion and good faith
consideration of each Party’s view on a particular matter before the JSC, the JSC is still unable after a period of [* * *] Business Days to reach a unanimous decision on such matter, then such matter shall be referred to the
Executive Officers for discussion. The Executive Officers shall confer with each other as soon as reasonably practicable (but in any event within [* * *] Business Days after such referral), and if the Executive Officers are unable
to reach a mutually agreeable decision on such matter within [* * *] Business Days after first conferring with each other, [* * *] shall have final decision-making authority; provided, however, that in no
event shall [* * *] be permitted to unilaterally decide such matter in a manner that (i) materially impairs or is reasonably likely to impair any rights or assets of Virobay or any of its Affiliates, or (ii) results or is
reasonably likely to result in an increased financial obligation for Virobay or any of its Affiliates or an increased obligation for Virobay or its Affiliates to utilize any personnel or other resources. 

(e) Virobay Right to Terminate Membership. Notwithstanding anything to the contrary in this Section 3.1, Virobay shall have the
right, in its sole discretion, to terminate its membership on the JSC at any time and thereby terminate any obligation it has to participate in such committee. Thereafter, any decisions or communications within the purview of such committee or
subcommittee shall henceforth be handled directly between the Parties. 

  
 19 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE 4 

DEVELOPMENT 
 4.1
Overview. The Parties desire and intend to conduct a Development Program under which Virobay will conduct preclinical development of the Compound and a Phase 1 b /2a Clinical Trial in the U.S., under the direction of the JSC and pursuant to a
Development Plan. Thereafter, either LEO will assume responsibility for Development of Licensed Products, or the Parties may agree that Virobay will conduct certain additional Development activities pursuant to an amended Development Plan, after
which LEO will assume all Development responsibilities for Licensed Products. 
 4.2 Development Program. 

(a) General. Following the Effective Date, Virobay shall conduct preclinical Development of Compounds and clinical Development of
Licensed Products in the Field in accordance with the terms of this Section 4.2 (such program, the “Development Program”). Virobay shall conduct such Development pursuant to a comprehensive written Development plan (the
“Development Plan”). Such Development Plan shall include a detailed plan for all preclinical and clinical Development activities conducted by Virobay and anticipated under the Development Program, including Manufacturing activities,
regulatory strategy and activities, and the timeline regarding such activities, and a budget for all such activities. In the event of any inconsistency between the Development Plan and this Agreement, the terms of this Agreement shall prevail. 

(b) Initial Development Plan and Amendments. The Parties have agreed on the initial Development Plan for VBY-891, a copy of which is
attached hereto as Exhibit D. From time to time prior to Development Transition (at least on an annual basis), the JSC shall prepare amendments, as appropriate, to the then-current Development Plan. Such amendments shall reflect any agreed
changes, re-prioritization of studies within, reallocation of resources with respect to, or additions to the Development Program. Once approved by the JSC, each updated or amended Development Plan shall become effective and supersede the previous
Development Plan as of the date of such approval or at such other time as decided by the JSC. 
 (c) Performance. Virobay shall use
Commercially Reasonably Efforts to conduct the Development activities assigned to it under the Development Plan in a timely and effective manner. 

4.3 Development Costs. LEO shall reimburse Virobay for Development activities to be conducted by Virobay under the Development Plan
according to the terms of Section 8.2, which shall include the reimbursement for supply of Compound at the Manufacturing Cost. 

4.4 Development Transition. Following Virobay’s completion of the Phase 1 b/2a Clinical Trial under the Development Plan, the
Parties will discuss whether LEO will assume responsibility for Development or whether Virobay will continue Development under an 

  
 20 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
amended Development Plan, subject to LEO’s reimbursement of costs incurred in accordance with the amended Development Plan. If the Parties agree that LEO will assume responsibility for
Development (or if the Parties fail to mutually agree that Virobay will continue Development), then Virobay will transfer to LEO all Virobay Know-How not previously provided to LEO, including all pre-clinical and clinical data and reports, according
to a process and timeline overseen by the JSC, and, for a three-month period, will provide reasonable assistance to LEO, at LEO’s cost, in LEO’s assumption of Development responsibility. If the Parties agree that Virobay will continue
Development, then the Parties will amend the Development Plan to include the relevant activities and a budget therefor, and the transition activities under this Section 4.4 will occur upon the completion of all such activities by Virobay. The
Parties intend that any such continued Development by Virobay under this Agreement will be in the U.S., and that LEO may concurrently conduct Development activities for Licensed Products outside the U.S. The JSC shall confirm the completion of all
transition activities under this Section 4.4. 
 4.5 Replacement Compounds. If the JSC (during Development by Virobay prior to
Development Transition) or LEO (after the Development Transition) determines that continued Development of the Compound is not feasible, whether for scientific, regulatory or safety reasons, then the Parties shall promptly meet and discuss in good
faith the substitution of a new compound for the then-current Compound, and shall use reasonable efforts to identify a substitute compound. If the Parties agree to any such substitution and any amended or new contract terms governing such
substitution, they shall promptly amend the Development Plan to include activities for such new Compound, and the previous compound shall not be further developed or licensed by Virobay in the Field. 

4.6 LEO’s Development Responsibilities. Following Development Transition, LEO shall be solely responsible for all Development of
Licensed Products in the Field, and shall use Commercially Reasonable Efforts (a) to Develop and seek Regulatory Approval for at least one (1) Licensed Product in the Field, initially for psoriasis, (b) upon termination of all
Development of Licensed Products for psoriasis, to Develop and seek Regulatory Approval for at least one (1) Licensed Product in another Indication in the Field, and (c) to obtain Regulatory Approval for at least one (1) Licensed
Product in the Field in the Territory. Following Development Transition, LEO shall keep the JSC apprised of the progress and results of LEO’s Development activities. 

4.7 Data Exchange and Use. Commencing promptly after the Effective Date, Virobay shall provide LEO with copies of or access to any data
related to the Compound or Licensed Products that is relevant to the Field and Controlled by Virobay, to the extent such data is in existence as of the Effective Date and was not previously provided to LEO. On at least a quarterly basis, Virobay
shall provide LEO with a summary of all data and results generated from its Development activities under this Agreement. In addition, upon reasonable request from LEO, Virobay shall provide LEO, at LEO’s expense, with complete copies of any of
such data and results. LEO shall have the right to use, without additional consideration, all data and results generated by or on behalf of Virobay under this Agreement, and subject to the terms of this Agreement. LEO shall have sole ownership of
all data and results generated by or on behalf of Virobay in the conduct of Clinical Trials under this Agreement (the “Virobay Development Data”), and Virobay hereby assigns, and shall assign, to LEO, all of its right, title and
interest in and to the Virobay Development Data (excluding any Patents claiming any inventions in any of the foregoing). Virobay shall have the right to use the Virobay Development Data in support of its other research and development programs. 

  
 21 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 4.8 Records and Reports. Each Party shall maintain complete, current and accurate
records of all Development activities conducted by it hereunder, and all data and other Information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the
Development activities in good scientific manner appropriate for regulatory and patent purposes. Each Party shall document all non-clinical studies and Clinical Trials in formal written study records according to applicable Laws, including
applicable national and international guidelines such as ICH, GCP, GLP and GMP. LEO shall have the right to review (with respect to Clinical Trial reports, before finalization) and copy such records maintained by Virobay at reasonable times and to
obtain access to the originals to the extent necessary or useful for regulatory and patent purposes, to the extent LEO has the right to conduct regulatory and patent activities under this Agreement. Virobay shall provide the JSC with written reports
detailing its Development activities under the Development Plan and the results of such activities at each regularly scheduled JSC meeting. The Parties shall discuss the status, progress and results of Virobay’s Development activities under the
Development Plan at such JSC meetings. 
 4.9 Compliance with Laws. Each Party shall conduct its activities under this Agreement in
good scientific manner and in compliance in all material respects with all applicable Laws, including applicable national and international guidelines such as ICH, GCP, GLP and GMP. 

4.10 Subcontracts. Virobay may perform its Development Program obligations under this Agreement through one or more subcontractors or
consultants approved by LEO, provided that in any event (a) Virobay shall remain responsible for the work allocated to, and payment to, such subcontractors and consultants as it selects to the same extent it would if it had done such work
itself; (b) the subcontractor shall undertake in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to Article 12 hereof, and
(c) the subcontractor shall agree in writing to assign all intellectual property developed in the course of performing any such subcontracted work to Virobay (provided, however, that Virobay may permit such subcontractor to retain ownership of
improvements to subcontractor’s background intellectual property so long as Virobay obtains a license to such improvements and such license may be sublicensed to LEO under Section 2.1(a) for no additional consideration). 

ARTICLE 5 
 REGULATORY
MATTERS 
 5.1 Regulatory Responsibilities. 

(a) Virobay shall prepare a draft IND for VBY-891 in the U.S. in accordance with the Development Plan, shall submit such draft IND to
LEO for review and comment, and shall include all reasonable comments of LEO thereto that are received by Virobay within [* * *] Business Days after LEO’s receipt thereof. Upon LEO’s approval, Virobay shall file the draft
IND with the FDA. LEO shall be responsible for all reasonable costs and expenses incurred 

  
 22 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
by Virobay to conduct such activities as provided in Section 4.3. Upon completion of all of Virobay’s activities under the Development Plan, Virobay shall assign and transfer the IND
for VBY-891 in the U.S. and related Regulatory Materials to LEO, at LEO’s expense. 
 (b) Following such transfer, LEO shall own
all Regulatory Materials (including all INDs, NDAs, MAAs and Regulatory Approvals) for each Licensed Product in the Field in the Territory. Other than the IND prepared by Virobay, LEO shall be solely responsible for preparing and filing any and all
other Regulatory Materials for each Licensed Product in the Field in the Territory, at its sole expense. Virobay shall assist and cooperate with LEO in connection with the preparation of such Regulatory Materials, as reasonably requested by LEO and
at LEO’s expense. 
 (c) Except as expressly contemplated by this Agreement or otherwise agreed to in writing by the Parties,
LEO shall be responsible for all Regulatory Materials and filings with Regulatory Authorities for the Compounds or the Licensed Products in the Territory and Virobay shall not submit any Regulatory Materials or seek Regulatory Approvals for the
Compounds or the Licensed Products in the Territory. LEO shall timely notify Virobay of any meeting (whether in person or by conference call) requested or scheduled with a Regulatory Authority with respect to the Compounds or Licensed Products.
Virobay may, on reasonable prior notice to LEO, have no more than [* * *] representatives participate in any such meeting. Except as provided in the preceding sentence, Virobay shall not communicate formally or informally with
respect to the Compounds or the Licensed Products with any Regulatory Authority, unless so required to comply with Applicable Laws, in which case Virobay shall promptly notify LEO of such requirement under Applicable Laws and, to the extent
practicable and permitted under applicable Laws, shall submit any proposed communication to LEO for prior approval or, if not practicable or permitted, shall provide LEO with a copy or summary thereof as soon as reasonably practicable thereafter.

 5.2 Notification of Threatened Action. Each Party shall immediately notify the other Party of any information it receives
regarding any threatened or pending action, inspection or communication by or from any Third Party, including a Regulatory Authority, which may materially affect the Development, Manufacturing, Commercialization or regulatory status of a Licensed
Product. Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action. If Virobay and LEO are not able to agree on the procedure, LEO shall have
the right to decide the appropriate action and Virobay shall reasonably cooperate to effect such action. 
 ARTICLE 6 

COMMERCIALIZATION 
 6.1
Commercialization Responsibilities. LEO will have the exclusive right to Commercialize and be solely responsible for all aspects of the Commercialization of each Licensed Product in the Field in the Territory, including: (a) developing and
executing a commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities regarding the price and reimbursement status of Licensed Products; (c) marketing and promotion; (d) booking sales and
distribution and performance of related services; (e) handling all aspects of order processing, invoicing and collection, inventory and receivables; (f) 

  
 23 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
providing customer support, including handling medical queries, and performing other related functions; and (g) conforming its practices and procedures to applicable Laws relating to the
marketing, detailing and promotion of Licensed Products in the Territory. LEO shall bear all of the costs and expenses incurred in connection with such Commercialization activities. 

6.2 Commercial Diligence. LEO shall use Commercially Reasonable Efforts to Commercialize each Licensed Product in each country in the
Territory in which it receives Regulatory Approval for such Licensed Product. For clarity, LEO shall have the right to withdraw a Licensed Product from the market in any country in the Territory if it is no longer feasible for LEO, in its exercise
of Commercially Reasonable Efforts, to continue to market and sell such Licensed Product in such country. 
 6.3 Commercialization
Reports. On an annual basis, LEO shall provide Virobay with a summary of LEO’s significant Commercialization activities with respect to each Licensed Product in the Territory, covering subject matter at a level of detail sufficient to
enable Virobay to determine LEO’s compliance with its diligence obligations pursuant to Section 6.2. 
 ARTICLE 7 

MANUFACTURE AND SUPPLY 

7.1 Responsibilities. Virobay shall be responsible for the supply of VBY-891 for Virobay’s and LEO’s use for preclinical and
clinical development under the Development Plan. LEO shall be responsible for all other Manufacture and supply of Compounds and Licensed Products in bulk and finished form for use under this Agreement, for Development and Commercialization purposes.

 7.2 Manufacturing Costs. LEO shall be responsible for all its costs and expenses for the Manufacture of the Compounds and Licensed
Products, and will reimburse Virobay for any supply of the Compounds and Licensed Products in accordance with Virobay’s Manufacturing Cost incurred in connection with Virobay’s supply for its own (or, if applicable, for LEO’s) use
under the Development Plan, in accordance with the terms of Section 8.2. 
 7.3 Subcontracts. Each Party may perform any of its
manufacturing and supply obligations under this Agreement through one or more Third Party manufacturers, provided that (a) in the case of Virobay, such subcontractor and Virobay’s agreement therewith is approved by LEO in advance in
writing, (b) such Party remains responsible for the work allocated to, and payment to, such Third Party manufacturer as it selects to the same extent it would if it had done such work itself, (c) the Third Party manufacturer undertakes in
writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to Article 12 hereof, and (d) the Third Party manufacturer agrees in writing to
assign all intellectual property developed in the course of performing any such manufacturing to the Party retaining such Third Party manufacturer. A Party may also subcontract work on terms other than those set forth in this Section 7.3, with
the prior approval of the other Party, not to be unreasonably withheld or delayed. The JSC shall discuss and oversee Virobay’s negotiations with any Third Party manufacturer of a Compound or Licensed Product. 

  
 24 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 7.4 Transfer of Manufacturing Technology. Promptly following the Effective Date,
Virobay shall transfer to LEO or a Third Party manufacturer reasonably designated by LEO all Virobay Know-How Controlled by Virobay or its Affiliate that, as of the date of transfer, is necessary or reasonably useful for LEO or such Third Party
manufacturer (as appropriate) to replicate the process employed by or on behalf of Virobay as of such date to Manufacture VBY-891 and, as applicable, other Compounds and Licensed Products. Such transferred Virobay Know-How shall include copies of
any contracts with a Third Party manufacturer that cover the Manufacture of any Compound or Licensed Product, to the extent such copies are Controlled by Virobay. From time to time thereafter, additional updates to such Manufacturing-related Virobay
Know-How previously transferred will occur in a timely manner, but in any event within [* * *] days after LEO’s reasonable request therefor, and shall include all such Information related to processes and formulations of
Compounds and Licensed Product developed or used under the Development Plan. In addition, upon LEO’s request following the determination under Section 4.4 that LEO will assume responsibility for Development, Virobay shall assign to LEO
those of its contracts with Third Party manufacturers that cover the Manufacture of any Compound or Licensed Product, to the extent assignable and related to a Compound or Licensed Product. For the avoidance of doubt, nothing in this
Section 7.4 with respect to Virobay’s obligation to transfer Manufacturing know-how to LEO shall limit Virobay’s right to retain and use any Manufacturing know-how in order to fulfill Virobay’s obligations under this Agreement.
The reasonable costs and expenses incurred by Virobay, including any internal personnel costs, in carrying out such transfer shall be reimbursed by LEO on a calendar quarter basis within [* * *] days after receipt of invoice
therefor from Virobay together with documentary evidence therefor. In addition, Virobay shall make available to LEO, on a reasonable consultation basis, advice of its technical personnel as may reasonably be requested by LEO in connection with such
transfer of Virobay Know-How. LEO agrees to reimburse Virobay for the reasonable charges for the time and expenses of such personnel when consulting for LEO. 

7.5 Use of Manufacturing Information. LEO and/or its Affiliates and Third Party manufacturer shall use any Information transferred
pursuant to Section 7.4 in accordance with the license granted in Section 2.1(a) and solely for the purpose of Manufacturing Compounds and Licensed Products for uses permitted under this Agreement, and for no other purpose (provided,
however, that, for the avoidance of doubt, such restriction shall not apply to the extent of any applicable exclusions in Article 12). LEO acknowledges and agrees that Virobay may condition its agreement to transfer any Virobay Know-How to a Third
Party manufacturer on the execution of a confidentiality agreement between such Third Party manufacturer and Virobay that contains terms substantially equivalent to those of Article 12 of this Agreement. 

ARTICLE 8 
 COMPENSATION

 8.1 Upfront Payment. Within [* * *] days after the execution of this Agreement by both Parties, LEO shall pay to
Virobay a one-time, non-refundable, non-creditable upfront payment of seven million Dollars ($7,000,000). 

  
 25 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 8.2 Virobay Development and Manufacturing Activities. LEO shall fund all internal FTE
costs (at the FTE Rate) and all amounts reasonably paid by Virobay to Third Parties (including the Manufacturing Cost for Compound or Licensed Product used under the Development Plan), in each case as incurred by Virobay to conduct the Development
Program in accordance with the Development Plan, including the budget therein. Within [* * *] days after each calendar quarter during the Development Program, Virobay shall provide LEO with an invoice and reasonable supporting
documentation for all internal FTE costs (at the FTE Rate) Virobay incurred in such quarter, and all amounts paid to Third Parties, to conduct the activities allocated to Virobay in accordance with the Development Plan and budget therein. LEO shall
pay each such invoice within [* * *] days after receipt thereof; provided that LEO shall not be required to reimburse any amounts for a particular activity in excess of the budgeted amount for such activity. 

  
 26 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 8.3 Development Milestone Payments. LEO shall make each of the following
non-refundable, non-creditable development milestone payments to Virobay upon the achievement (a) by Virobay (for milestones 1, 2 and 3), (b) by Virobay or by LEO, its Affiliates, or their respective sublicensees (for milestone 4),
(c) by LEO, its Affiliates or their respective sublicensees (for milestones 5 through 8), or (d) by LEO or its Affiliates (for milestone 9) of the following development events. LEO shall pay to Virobay each such amount within
[* * *] days after the achievement of the applicable milestone event. 
  

							
	 	  	 Development Milestone Event
	  	
Milestone Payment
(adjusted as
provided below for
additional
Indications)
	 
	1	  	 [* * *]
	  	 	[* * *]	  
	2	  	 [* * *]
	  	 	[* * *]	  
	3	  	 Either of the following (i.e., 3(A) or 3(B), but not both) shall apply:
	  			
		  	 3(A). If, [* * *], then the following milestone shall apply:
	  			
		  	 [* * *]
	  	 	[* * *]	  
		  	 3(B). If, [* * *], then the following two (2) milestones shall apply:
	  			
			
		  	 (1) [* * *]; and
	  	 	[* * *]	  
		  	 (2) [* * *]
	  	 	[* * *]	  
	4	  	 Each of the following shall apply, depending on the relevant Indication:
	  			
		  	 [* * *]
	  	 	[* * *]	  
		  	 [* * *]
	  	 	[* * *]	  
		  	 [* * *]
	  	 	[* * *]	  
		  	 [* * *]
	  	 	[* * *]	  
	5	  	 [* * *]
	  	 	[* * *]	  
		  	 [* * *]
	  	 	[* * *]	  
	6	  	 [* * *]
	  	 	[* * *]	  
	7	  	 [* * *]
	  	 	[* * *]	  
	8	  	 [* * *]
	  	 	[* * *]	  
	9	  	 [* * *]
	  	 	[* * *]	  

  
 27 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 As used above “[* * *]” means the product of
(i) [* * *] and (ii) [* * *], and “[* * *]” means the product of (i) [* * *] and (ii) [* * *]. 

Milestone payments 1, 2, and 3 shall be made only once for the first occurrence of each milestone event. 

Milestone payments 5 through 9 are payable one time for each different Indication (whether with the same or different Licensed Product)
to achieve the milestone event, as follows: for the first Indication to achieve the milestone, the amount payable is the full amount set forth in the table above; for the second Indication to achieve the milestone, the amount payable is
[* * *] of the amount set forth in the table above; for the third Indication to achieve the milestone, the amount payable is [* * *] of the amount set forth in the table above; and for the fourth and all subsequent
Indications to achieve the milestone, the amount payable is [* * *] of the amount set forth in the table above. 

Milestone payment 9 shall be payable only if the milestone is achieved by LEO and its Affiliates, and shall not be payable if achieved by a
sublicensee. 
 8.4 Sales Milestones. LEO shall make each of the following one-time, non-refundable, non-creditable sales milestone
payments to Virobay when the aggregate annual Net Sales by LEO, its Affiliates and their respective sublicensees of Licensed Products in the Territory in a calendar year first reach the amount specified below. LEO shall pay to Virobay such amount
within [* * *] days after the completion of the audit of the financial statements for the calendar year in which such event is achieved for the first time. For clarity, the milestone payments in this Section 8.4 shall be
additive such that if more than one milestone below is met in the same calendar year, LEO shall pay all applicable one-time payments to Virobay for that calendar year. 
  

					
	 Sales Milestone Event
	  	Milestone Payment	 
	 The aggregate Net Sales of Licensed Products in the Territory in a calendar year equal or exceed [* * *]
	  	 	[* * *]	  
	 The aggregate Net Sales of Licensed Products in the Territory in a calendar year equal or exceed [* * *]
	  	 	[* * *]	  
	 The aggregate Net Sales of Licensed Products in the Territory in a calendar year equal or exceed [* * *]
	  	 	[* * *]	  
	 The aggregate Net Sales of Licensed Products in the Territory in a calendar year equal or exceed [* * *]
	  	 	[* * *]	  
	 The aggregate Net Sales of Licensed Products in the Territory in a calendar year equal or exceed [* * *]
	  	 	[* * *]	  

  
 28 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 8.5 Royalties. 

(a) Royalty Rates. Subject to Sections 8.5(b)-(d), LEO shall pay to Virobay non-refundable, non-creditable royalties on aggregate
annual Net Sales of all Licensed Products covered by any Virobay Patent in the Field in the Territory during the applicable Royalty Term, as calculated by multiplying the applicable royalty rate by the corresponding amount of incremental Net Sales
of all Licensed Products in the Territory in each calendar year. 
  

					
	 Annual Net Sales of Licensed Products in the Territory
	  	 Royalty Rate
	 
	 For that portion of annual aggregate Net Sales of Licensed Products less than or equal to [* * *]
	  	 	[* * *]	% 
	 For that portion of annual aggregate Net Sales of Licensed Products greater than [* * *] and less than or equal to
[* * *]
	  	 	[* * *]	% 
	 For that portion of annual aggregate Net Sales of Licensed Products greater than [* * *] and less than or equal to
[* * *]
	  	 	[* * *]	% 
	 For that portion of annual aggregate Net Sales of Licensed Products greater than [* * *] and less than or equal to
[* * *]
	  	 	[* * *]	% 
	 For that portion of annual aggregate Net Sales of Licensed Products greater than [* * *] and less than or equal to
[* * *]
	  	 	[* * *]	% 
	 For that portion of annual aggregate Net Sales of Licensed Products greater than [* * *]
	  	 	[* * *]	% 

  
 29 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 For example, if aggregate annual Net Sales of all Licensed Products in the Territory is
$[* * *] billion, then royalties payable by LEO equal ([* * *]% of $[* * *] million) + ([* * *]% of $[* * *] million) + ([* * *]% of
$[* * *] million) + ([* * *]% of $[* * *] million) + ([* * *]% of $[* * *] million) = $[* * *] million. 

(b) Royalty Term. Royalties shall be paid under this Section 8.5, on a country-by-country and Licensed Product-by-Licensed Product
basis, during the period of time beginning from the First Commercial Sale of such Licensed Product in such country until the later of: (i) the expiration of the last-to-expire Valid Claim in any Virobay Patent in such country claiming the
composition of matter, manufacture or method of use of the Licensed Product for an Indication for which Regulatory Approval has been obtained; and (ii) the fifteenth (15th) anniversary
of the First Commercial Sale of such Licensed Product in such country (the “Royalty Term”). 
 (c) Generic
Reduction. If, in any country in the Territory during the Royalty Term for a Licensed Product, a Generic Product to such Licensed Product is sold, then from the [* * *] and for all calendar quarters thereafter during which the
Generic Product continues to be sold in such country, the royalty applicable to sales of such Licensed Product in such country shall be [* * *] of Net Sales of such Licensed Product in such country; provided, however, that if, prior
to the expiration of the last-to-expire Valid Claim in any Virobay Patent in such country claiming the composition of matter, manufacture or method of use of such Licensed Product for an Indication for which Regulatory Approval has been obtained,
Virobay owes royalties under the [* * *] with respect to sales of such Licensed Product in such country, the royalty payable by LEO shall be increased to the royalty owed by Virobay, for so long as such royalty is owed under
[* * *]. 

  
 30 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (d) Royalty Reports and Payments. All amounts payable to Virobay pursuant to this
Section 8.5 shall be paid in Dollars within [* * *] days after the end of each calendar quarter with respect to Net Sales in such calendar quarter. Each payment of royalties due to Virobay shall be accompanied by a statement,
on a country-by-country basis, of the amount of gross sales of Licensed Products during the applicable calendar quarter, a calculation of Net Sales showing the aggregate deductions from gross sales provided for in the definition of Net Sales during
such calendar quarter, and a calculation of the amount of royalty payment due on such sales for such calendar quarter. 
 8.6 Third Party
Payments. 
 (a) Virobay Obligations. Virobay will be solely responsible for all amounts owed to Third Parties after the
Effective Date pursuant to agreements between Virobay and Third Parties with respect to Compounds and Licensed Products that were entered into prior to the Effective Date, including the [* * *]. 

(b) LEO Obligations. LEO will be solely responsible for all amounts owed to Third Parties after the Effective Date pursuant to any
future license or technology acquisition agreement under which LEO obtains rights to Third Party Patents or Information related to the Development and Commercialization of the Licensed Product by LEO, its Affiliates and their respective
sublicensees. 
 8.7 Sublicense Revenue. LEO shall pay to Virobay, within [* * *] days after the end of each
calendar quarter, an amount equal to [* * *] of all Sublicense Revenue received by LEO in such calendar quarter; provided, however, that in the event that LEO receives any payments from a sublicensee as a result of an event
triggering milestone payment 9 under Section 8.3 [* * *], LEO shall be permitted to exclude this amount from Sublicense Revenue. In the event that LEO calculates Sublicense Revenue by allocating payments among various licensed
intellectual properties and/or licensed territories (as permitted under the definition of Sublicense Revenue in Article 1), LEO’s payment shall be accompanied by a memorandum detailing the rationale and methodology for such allocation, and LEO
shall deliver to Virobay any information or document that Virobay may reasonably request in order to verify such rationale and methodology. 

8.8 Foreign Exchange. Monthly Sales invoiced in other currencies than US Dollars shall be converted from invoicing currency to US
Dollars equivalent. The exchange rate of invoicing currency used in calculating the amount of US Dollars must be the closing exchange rates published on the last working day of the month in The Financial Times. 

8.9 Payment Method; Late Payments. All payments due to Virobay hereunder shall be made in Dollars by wire transfer of immediately
available funds into an account designated by Virobay. If Virobay does not receive payment of any undisputed sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to Virobay until the date of payment at the
per annum rate of [* * *] over the then-current EUROBOR rate reported in The Financial Times or the maximum rate allowable by applicable Laws, whichever is lower. 

  
 31 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 8.10 Records; Audits. LEO and its Affiliates and sublicensees will maintain complete
and accurate records in sufficient detail to permit Virobay to confirm the accuracy of the calculation of royalty payments and the achievement of sales milestone events. Virobay and its Affiliates will maintain complete and accurate records in
sufficient detail to permit LEO to confirm the accuracy of the calculation of FTEs and Third Party payments for Development or Manufacturing reimbursed by LEO under Section 8.2. Upon reasonable prior notice, such records shall be available
during regular business hours for a period of [* * *] years from the end of the calendar year to which they pertain for examination, not more often than once each calendar year, by an independent certified public accountant selected
by the auditing Party and reasonably acceptable to the audited Party, for the sole purpose of verifying the accuracy of the financial reports furnished by the other Party pursuant to this Agreement. Any such auditor shall not disclose the audited
Party’s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments due by one Party to the other Party under this
Agreement. Any amounts shown to be owed but unpaid shall be paid within [* * *] days from the accountant’s report, plus interest (as set forth in Section 8.9) from the original due date. The auditing Party shall bear the
full cost of such audit unless such audit discloses an underpayment by the audited Party of more than [* * *] of the amount due, in which case the audited Party shall bear the full cost of such audit. 

8.11 Taxes. 
 (a)
Taxes on Income. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. 

(b) Tax Cooperation. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding
or similar obligations in respect of royalties, milestone payments, and other payments made by LEO to Virobay under this Agreement. To the extent LEO is required to deduct and withhold taxes on any payment to Virobay, LEO shall pay the amounts of
such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Virobay an official tax certificate or other evidence of such withholding sufficient to enable Virobay to claim such payment of taxes. Virobay shall provide
LEO any tax forms that may be reasonably necessary in order for LEO not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the
recovery, as permitted by applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value
added tax. 
 ARTICLE 9 

INTELLECTUAL PROPERTY MATTERS 

9.1 Ownership of Inventions. Subject to Section 4.6, each Party shall own any inventions, whether or not patentable, made solely
by its own employees, agents, or independent 

  
 32 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
contractors in the course of conducting its activities under this Agreement, together with all intellectual property rights therein (“Sole Inventions”). The Parties shall jointly
own any inventions that are made jointly by employees, agents, or independent contractors of each Party in the course of performing activities under this Agreement, together with all intellectual property rights therein (“Joint
Inventions”). Inventorship shall be determined in accordance with U.S. patent laws. All Patents claiming patentable, jointly owned Joint Inventions shall be referred to herein as “Joint Patents”. Except to the extent either
Party is restricted by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice and exploit the Joint Inventions and Joint Patents without the duty of accounting or seeking consent from the other Party.

 9.2 Disclosure of Inventions. Each Party shall promptly disclose to the other Party, and in any event prior to any Patent filing
with respect to such inventions, all Sole Inventions and Joint Inventions made by such Party prior to Development Transition or, in the case of Virobay, made thereafter to the extent that Virobay conducts any activities under this Agreement,
including any invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing inventions that are either Sole Inventions or Joint Inventions, and all Information relating to such
inventions to the extent necessary or useful for the preparation, filing and maintenance of any Patent with respect to such invention. 

9.3 Prosecution of Patents. 

(a) Virobay Patents. 

(i) As between the Parties, Virobay shall have the first right to prepare, file, prosecute and maintain the Virobay Patents, at
Virobay’s cost and expense. Virobay shall timely provide LEO reasonable opportunity to review and comment on such prosecution efforts regarding such Virobay Patents, as follows. Virobay shall timely provide LEO with copies of all material
communications from any patent authority regarding such Virobay Patents, and shall timely provide LEO, for its review and comment, with drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in
advance of submitting such filings or responses. Virobay shall consider in good faith and shall implement as appropriate any reasonable comments thereto provided by LEO in connection with the prosecution of such Virobay Patents. Virobay shall use
Commercially Reasonable Efforts (1) to ensure that all Virobay Patents that are pending patent applications issue as patents and (2) to obtain the broadest claim coverage for the Virobay Patents. 

(ii) Promptly after the European Patent Office issues a “Notice of Intention to Grant” (or equivalent) for any European
patent in the Virobay Patents, Virobay shall solicit LEO’s input on the particular countries in which LEO desires to validate such European patent. The Parties shall use good faith efforts to agree on any such countries; provided that Virobay
shall validate such patent in each country reasonably requested by LEO. 
 (iii) If Virobay decides to cease the prosecution or
maintenance of any Virobay Patents, it shall notify LEO in writing sufficiently in advance so that LEO may, at its discretion and by written notice to Virobay, assume the responsibility for the prosecution or maintenance of such Virobay Patents on
behalf of Virobay, at LEO’s cost and expense (but with 

  
 33 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
the continued cooperation of Virobay as provided in Section 9.3(d)). In order to preserve LEO’s rights as set forth in the first sentence of this Section 9.3(a)(iii), Virobay
shall, to the extent that Virobay grants any Third Party the right to prosecute or maintain any Virobay Patent on Virobay’s behalf, (A) retain, either for itself directly or on behalf of LEO, the right to prosecute or maintain such Virobay
Patent if such Third Party decides to cease the prosecution or maintenance thereof and (B) obligate such Third Party to provide the type of assistance and cooperation contemplated in Section 9.3(d). 

(b) Joint Patents. 

(i) As between the Parties, LEO shall have the first right to prepare, file, prosecute and maintain the Joint Patents in the
Territory. If LEO decides to cease the prosecution or maintenance of any Joint Patents, it shall timely notify Virobay in writing sufficiently in advance so that Virobay may, at its discretion, assume the responsibility for the prosecution or
maintenance of such Patents. Except as provided below, the out-of-pocket costs of such preparation, filing, prosecution and maintenance shall be shared by the Parties equally. 

(ii) The Party that is responsible for preparing, filing, prosecuting, and maintaining a particular Joint Patent (the
“Prosecuting Party”) shall timely provide the other Party reasonable opportunity to review and comment on such prosecution efforts regarding such Joint Patent, as follows. The Prosecuting Party shall timely provide the other Party
with copies of all material communications from any patent authority regarding such Joint Patent, and shall timely provide the other Party, for its review and comment, with drafts of any material filings or responses to be made to such patent
authorities a reasonable amount of time in advance of submitting such filings or responses. The Prosecuting Party shall consider in good faith and shall implement as appropriate any reasonable comments thereto provided by the other Party in
connection with the prosecution of such Joint Patent. The Prosecuting Party shall use Commercially Reasonable Efforts to obtain the broadest claim coverage for such Joint Patent. Each Party agrees to provide the other Party with all information
necessary or desirable to enable the other Party to comply with the duty of candor/duty of disclosure requirements of any patent authority. Either Party may determine that it is no longer interested in supporting the continued prosecution or
maintenance of a particular Joint Patent in a country or jurisdiction, in which case: (A) the disclaiming Party shall, if requested in writing by the other Party, assign its ownership interest in such Joint Patent in such country or
jurisdiction to the other Party for no additional consideration; and (B) if such assignment is effected, any such Joint Patent would thereafter be deemed a Virobay Patent in the case of assignment to Virobay, or a LEO Patent in the case of
assignment to LEO. 
 (c) LEO Patents. As between the Parties, LEO shall have the sole right to prepare, file, prosecute and maintain
the LEO Patents in the Territory, at LEO’s cost and expense. LEO shall provide Virobay reasonable opportunity to review and comment on such prosecution efforts regarding such LEO Patents, as follows. LEO shall provide Virobay with copies of all
material communications from any patent authority regarding such LEO Patents, and shall provide Virobay, for its review and comment, with drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time
in advance of submitting such filings or responses. LEO shall consider in good faith any reasonable comments thereto provided by Virobay in connection with the prosecution of such LEO Patents. 

  
 34 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (d) Cooperation. Each Party shall provide the other Party all reasonable assistance
and cooperation, at the other Party’s request and expense, in the patent prosecution efforts provide above in this Section 9.3, including providing any necessary powers of attorney and executing any other required documents or instruments
for such prosecution. 
 9.4 Enforcement of Virobay Patents and Joint Patents. 

(a) Notification. If either Party become aware of any existing or threatened infringement of the Virobay Patents or Joint Patents in
the Field in the Territory, which infringing activity (i) involves the using, making, importing, exporting, offering for sale or selling the Compounds or Licensed Products or a competitive product in the Field, or (ii) results from the
filing of an ANDA under Section 505(j) of the FD&C Act that seeks regulatory approval in the Field, names a Compound or Licensed Product as a reference listed drug, and includes a certification under Section 505(j)(2)(A)(vii)(IV) (such
filing, a “Paragraph IV Certification”) (collectively, a “Product Infringement”), it shall promptly notify the other Party in writing to that effect, and the Parties will consult with each other regarding any
actions to be taken with respect to such Product Infringement. 
 (b) Enforcement Rights. For any Product Infringement, each Party
shall share with the other Party all Information available to it regarding such alleged infringement. LEO shall have the first right, but not the obligation, to bring an appropriate suit or other action against any person or entity engaged in such
Product Infringement, at LEO’s cost and expense. Except in the case of a Paragraph IV Certification (which is addressed below), LEO shall have a period of [* * *] days after its receipt or delivery of notice under
Section 9.4(a) to elect to so enforce the Virobay Patents or Joint Patents in the Territory, and [* * *] days thereafter to commence such enforcement (or to settle or otherwise secure the abatement of such Product
Infringement). If LEO fails to commence a suit to enforce the applicable Virobay Patents or Joint Patents or to settle or otherwise secure the abatement of such Product Infringement within such period (or in the case of a Paragraph IV Certification,
if LEO fails to do so within [* * *] days of the filing of such Paragraph IV Certification), then Virobay shall have the right, but not the obligation, to commence a suit or take action to enforce such Virobay Patents or Joint
Patents against such Product Infringement in the Territory at its own cost and expense. In such event, LEO shall take appropriate actions in order to enable Virobay to commence a suit or take the actions set forth in the preceding sentence. 

(c) Collaboration. Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing
Party’s request and expense, including joining such action as a party plaintiff if required by applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such
enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, and shall seek consent of the other Party in any important aspects of such enforcement, including determination of litigation strategy and filing of
material papers to the competent court, which consent shall not be unreasonably withheld or delayed. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such
Party shall at all times cooperate fully with the enforcing Party. 

  
 35 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (d) Settlement. LEO shall not settle any claim, suit or action that it brought under
Section 9.4(b) in any manner that would negatively impact the applicable Virobay Patents or Joint Patents, without the prior written consent of Virobay, which consent shall not be unreasonably withheld or delayed. 

(e) Expenses and Recoveries. The enforcing Party bringing a claim, suit or action under Section 9.4(b) shall be solely responsible
for any expenses incurred by such Party as a result of such claim, suit or action. If such Party recovers monetary damages in such claim, suit or action, such recovery shall be allocated first to the reimbursement of any expenses incurred by the
Parties in such litigation (including, for this purpose, a reasonable allocation of expenses of internal counsel), and any remaining amounts shall be retained by the Party bringing suit, provided that, in the event LEO is the Party bringing suit,
(i) any remaining amounts (other than enhanced or punitive damages) shall be included in Net Sales subject to the royalty payment by LEO to Virobay pursuant to Section 8.5 and (ii) any enhanced or punitive damages shall be allocated
[* * *] to LEO and [* * *] to Virobay. 
 (f) Infringement Other Than a Product Infringement. For
any and all infringement of any Virobay Patents other than a Product Infringement, as between the Parties, Virobay shall have the sole and exclusive right to bring an appropriate suit or other action against any person or entity engaged in such
other infringement, in its sole discretion, and shall bear all related expenses and retain all related recoveries; provided, however, that Virobay shall update and reasonably consult with LEO about the infringement and suit or other action. 

9.5 Enforcement of LEO Patents. LEO shall have the sole right, but not the obligation, to bring an appropriate suit or other action
against any person or entity allegedly infringing any LEO Patents. Virobay shall provide reasonable assistance to LEO in such enforcement, at LEO’s request and expense. LEO shall keep Virobay regularly informed of the status and progress of
such enforcement efforts, and shall reasonably consider Virobay’s comments on any such efforts. 
 9.6 Patents Licensed From Third
Parties. Each Party’s rights under this Article 9 with respect to the prosecution, maintenance and enforcement of any Virobay Patent that is licensed by Virobay from a Third Party shall be subject to the rights of such Third Party to
prosecute, maintain and enforce such Patent. 
 9.7 Infringement of Third Party Rights in the Territory. Subject to Article 11, if
any Licensed Product used or sold by LEO, its Affiliates or sublicensees becomes the subject of a Third Party’s claim or assertion of infringement of a Patent, LEO shall promptly notify Virobay and the Parties shall agree on and enter into a
“common interest agreement” wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties shall promptly meet to consider the claim or assertion and the appropriate course
of action. LEO shall be solely responsible for the defense of any such infringement claims, at LEO’s cost and expense. 
 9.8
Parties’ Patent Rights. If any Virobay Patent or Joint Patent becomes the subject of any proceeding commenced by a Third Party within the Territory in connection with an opposition, reexamination request, action for declaratory judgment,
nullity action, interference or other attack upon the validity, title or enforceability thereof (except insofar as such action is a 

  
 36 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
counterclaim to or defense of, or accompanies a defense of, an action for infringement against a Third Party under Section 9.4 or 9.5, in which case the provisions of Section 9.4 or
9.5, as applicable, shall govern), then the Party then-responsible for the prosecution and maintenance of such Patent shall control such defense. Each Party shall be responsible for all reasonable and documented costs and expenses incurred by such
Party in any defense controlled by such Party under this Section 9.8. The controlling Party shall permit the non-controlling Party to participate in the proceeding to the extent permissible under applicable Laws, and to be represented by its
own counsel in such proceeding, at the non-controlling Party’s expense. If either Party decides that it does not wish to defend against such action, then the other Party shall have a backup right to assume defense of such Third-Party action at
its own expense. Any awards or amounts received in defending any such Third-Party action shall be allocated between the Parties as provided in Section 9.4(e). 

9.9 Orange Book Listing. Upon a Party’s receipt of a notice of allowance (or equivalent) of an applicable Virobay Patent, Virobay
shall promptly provide LEO with all information reasonably required by LEO to list such Virobay Patent in the Orange Book maintained by the FDA or similar or equivalent patent listing source, if any, in other countries in the Territory
(collectively, “Orange Book and Equivalents”). LEO shall have the sole right to determine which patent shall be included in the Orange Book and to file supplementary protection certificates. LEO shall promptly file,
consistent with applicable Laws, all appropriate information with the Regulatory Authorities in applicable countries where LEO deems necessary, including the U.S., to list applicable Virobay Patents, Joint Patents and LEO Patents in the Orange Book
and Equivalents, and LEO shall use Commercially Reasonable Efforts to obtain and maintain such listings. 
 9.10 Personnel
Obligations. Prior to beginning work under this Agreement relating to any Development or Commercialization of a Compound or Licensed Product, each employee, agent or independent contractor of LEO or Virobay or of either Party’s respective
Affiliates shall be bound by invention assignment obligations that are consistent with the obligations of LEO or Virobay, as applicable, in this Article 9, including without limitation: (a) promptly reporting any invention, discovery, process
or other intellectual property right; (b) assigning to LEO or Virobay, as applicable, all of his or her right, title and interest in and to any invention, discovery, process or other intellectual property right; (c) cooperating in the
preparation, filing, prosecution, maintenance and enforcement of any Patent; and (d) performing all acts and signing, executing, acknowledging and delivering any and all documents required for effecting the obligations and purposes of this
Agreement. 
 9.11 Trademarks. LEO shall have the right to brand the Licensed Products in the Territory using LEO related trademarks
and any other trademarks and trade names it determines appropriate for the Licensed Products, which may vary by country or within a country (“Product Marks”), provided that LEO shall not, and shall ensure that its Affiliates and
sublicensees will not, make any use of the trademarks or house marks of Virobay (including Virobay’s corporate name) or any trademark confusingly similar thereto. LEO shall own all rights in the Product Marks and shall register and maintain, at
its own cost and expense, the Product Marks in the countries and regions in the Territory that it determines reasonably necessary. 

  
 37 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE 10 

REPRESENTATIONS AND WARRANTIES; COVENANTS 

10.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as follows: 

(a) Corporate Existence. As of the Effective Date, it is a company or corporation duly organized, validly existing, and in good
standing under the Laws of the jurisdiction in which it is incorporated. 
 (b) Corporate Power, Authority and Binding Agreement. As
of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize
the execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such
Party that is enforceable against it in accordance with its terms. 
 10.2 Additional Representations and Warranties of Virobay.
Virobay represents and warrants to LEO as follows, as of the Effective Date: 
 (a) Title; Encumbrances. It has sufficient legal
and/or beneficial title, ownership or license, free and clear from any mortgages, pledges, liens, security interests, conditional and installment sale agreement, encumbrances, charges or claim of any kind, of the Virobay Technology to grant the
licenses to LEO granted pursuant to this Agreement; 
 (b) Notice of Infringement or Misappropriation. It has not received any
written notice from any Third Party asserting or alleging, nor does Virobay have any knowledge of any reasonable basis for such assertion or allegation, that any research, manufacture or development of the Compounds or Licensed Products by Virobay
prior to the Effective Date infringed or misappropriated the intellectual property rights of such Third Party; 
 (c) Third Party
Technology. To Virobay’s knowledge, the manufacture, development and commercialization of Compounds and Licensed Products will not infringe any intellectual property rights of a Third Party; 

(d) No Proceeding. There are no pending, and to Virobay’s knowledge, no threatened, adverse actions, suits or proceedings against
Virobay involving Virobay Technology, the Compounds or Licensed Products; 
 (e) Virobay Patents. Exhibit B lists all Patents
owned or Controlled by Virobay as of the Effective Date that claim the composition, use or manufacture of the Compound; 
 (f)
Disclosure. Virobay has made available to LEO all material written information in Virobay’s possession or Control as of the Effective Date and requested by LEO in writing relating to VBY-891, and to Virobay’s knowledge, all such
information provided by Virobay is true and correct; and 

  
 38 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (g) [* * *] Agreement. Virobay has provided LEO with a true and complete
copy of the [* * *] Agreement, which is in full force and effect; Virobay is not and to Virobay’s knowledge, [* * *] is not in default under the [* * *] Agreement with respect to a material
obligation thereunder; and neither such party has claimed or, to Virobay’s knowledge, has grounds upon which to claim that the other party is in default with respect to a material obligation under such agreement. 

10.3 Mutual Covenants. 

(a) No Debarment. In the course of the Development of the Licensed Product, each Party shall not use any employee or consultant who has
been debarred by any Regulatory Authority, or, to such Party’s knowledge, is the subject of debarment proceedings by a Regulatory Authority. Each Party shall notify the other Party promptly upon becoming aware that any of its employees or
consultants has been debarred or is the subject of debarment proceedings by any Regulatory Authority. 
 (b) Compliance. Each Party
and its Affiliates shall comply in all material respects with all applicable Laws in the Development and Commercialization of Licensed Products and performance of its obligations under this Agreement, including, to the extent applicable to such
Party and its activities hereunder, the statutes, regulations and written directives of the FDA, the EMA and any Regulatory Authority having jurisdiction in the Territory, the FD&C Act, the Prescription Drug Marketing Act, the Federal Health
Care Programs Anti-Kickback Law, 42 U.S.C. 1320a-7b(b), the statutes, regulations and written directives of Medicare, Medicaid and all other health care programs, as defined in 42 U.S.C. § 1320a-7b(f), and the Foreign Corrupt Practices Act of
1977, each as may be amended from time to time. 
 10.4 Disclaimer. LEO understands that the Compounds and Licensed Products are the
subject of ongoing research and development and that Virobay cannot assure the safety or usefulness of any Compound or Licensed Product. In addition, Virobay makes no warranties except as set forth in this Article 10 concerning the Virobay
Technology. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION
OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 

ARTICLE 11 

INDEMNIFICATION 
 11.1
Indemnification by Virobay. Virobay shall defend, indemnify, and hold LEO and its Affiliates and their respective officers, directors, employees, and agents (the “LEO Indemnitees”) harmless from and against any and all Third
Party claims, suits, proceedings, 

  
 39 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
damages, expenses (including court costs and reasonable attorneys’ fees and expenses) and recoveries (collectively, “Claims”) to the extent that such Claims arise out of,
are based on, or result from (a) Virobay’s negligent performance of the activities allocated to Virobay under the Development Plan, (b) the breach of any of Virobay’s obligations, representations or warranties under this
Agreement, or (c) the willful misconduct or negligent acts of Virobay, its Affiliates, or the officers, directors, employees, or agents of Virobay or its Affiliates. The foregoing indemnity obligation shall not apply to the extent that
(i) the LEO Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Virobay’s defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from, is based on, or
results from any activity set forth in Section 11.2(b) or 11.2(c) for which LEO is obligated to indemnify the Virobay Indemnitees under Section 11.2. 

11.2 Indemnification by LEO. LEO shall defend, indemnify, and hold Virobay and its Affiliates and their respective officers, directors,
employees, and agents (the “Virobay Indemnitees”) harmless from and against any and all Claims to the extent that such Claims arise out of, are based on, or result from (a) the Development or Commercialization of Compounds or
Licensed Products by or on behalf of LEO or its Affiliates or sublicensees (other than by Virobay), or (b) the breach of any of LEO’s obligations, representations or warranties under this Agreement, or (c) the willful misconduct or
negligent acts of LEO, its Affiliates, or the officers, directors, employees, or agents of LEO or its Affiliates. The foregoing indemnity obligation shall not apply to the extent that (i) the Virobay Indemnitees fail to comply with the
indemnification procedures set forth in Section 11.3 and LEO’s defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from, is based on, or results from any activity set forth in Section 11.1(b) or
11.1(c) for which Virobay is obligated to indemnify the LEO Indemnitees under Section 11.1. 
 11.3 Indemnification Procedures. The
Party claiming indemnity under this Article 11 (the “Indemnified Party”) shall give written notice to the Party from whom indemnity is being sought (the “Indemnifying Party”) promptly after learning of such Claim.
The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of the Claim for which indemnity is being sought. The Indemnified Party may participate
in and monitor such defense with counsel of its own choosing at its sole expense; provided, however, the Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party shall
not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. So long as the Indemnifying Party is actively defending the Claim in good
faith, the Indemnified Party shall not settle or compromise any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the
Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with,
or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Article 11. 

  
 40 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 11.4 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS
INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 OR 11.2 OR DAMAGES AVAILABLE FOR BREACHES OF ARTICLE 12. 

11.5 Insurance. Each Party shall procure and maintain insurance, including product liability insurance, adequate to cover its
obligations hereunder and consistent with normal business practices of prudent companies similarly situated at all times during which any Licensed Product is being clinically tested in human subjects or commercially distributed or sold by such Party
and for the [* * *] year period thereafter. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this Article 11. Each
Party shall provide the other Party with written evidence of such insurance upon request. Each Party shall provide the other Party with written notice at least [* * *] days prior to the cancellation,
non-renewal or material change in such insurance. 
 ARTICLE 12 

CONFIDENTIALITY 
 12.1
Confidentiality. Each Party agrees that, during the Term and for a period of [* * *] years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as
provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information furnished to it by the other Party pursuant to this Agreement, except to the extent expressly
authorized by this Agreement or otherwise agreed in writing by the Parties. The foregoing confidentiality and non-use obligations shall not apply to any portion of the other Party’s Confidential Information that the receiving Party can
demonstrate by competent written proof: 
 (a) was already known to the receiving Party or its Affiliate, other than under an
obligation of confidentiality, at the time of disclosure by the other Party; 
 (b) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the receiving Party; 
 (c) became generally available to the
public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 

(d) was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal right to make such disclosure and who did
not obtain such information directly or indirectly from the other Party; or 
 (e) was independently discovered or developed by the
receiving Party or its Affiliate without access to or aid, application or use of the other Party’s Confidential Information, as evidenced by a contemporaneous writing. 

  
 41 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Notwithstanding the definition of “Confidential Information” in Article 1, all
Information generated under the Development Program, whether generated by one or both Parties, shall be deemed the Confidential Information of LEO. In addition, the exceptions set forth in subsections (a) and (e) shall not apply to
Information generated during or resulting from the Development Program, which Information shall be deemed Confidential Information regardless of whether such Information satisfies the criteria set forth in one or both subsections. 

12.2 Authorized Disclosure. Notwithstanding the obligations set forth in Section 12.1, a Party may disclose the other Party’s
Confidential Information and the terms of this Agreement to the extent: 
 (a) such disclosure is reasonably necessary (i) for
filing or prosecuting Patents as contemplated by this Agreement; (ii) to comply with the requirements of Regulatory Authorities with respect to obtaining and maintaining Regulatory Approval of a Licensed Product; or (iii) for prosecuting
or defending litigation as contemplated by this Agreement; 
 (b) such disclosure is reasonably necessary to its employees, agents,
consultants, contractors, licensees or sublicensees on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are bound by written obligations
of confidentiality and non-use consistent with those contained in this Agreement; 
 (c) such disclosure is reasonably necessary to
any bona fide potential or actual investor, acquiror, merger partner, or other financial or commercial partner for the sole purpose of evaluating an actual or potential investment, acquisition or other business relationship; provided that in
connection with such disclosure, such Party shall use all reasonable efforts to inform each disclosee of the confidential nature of such Confidential Information and cause each disclosee to treat such Confidential Information as confidential; or

 (d) such disclosure is reasonably necessary to comply with applicable Laws, including regulations promulgated by applicable
security exchanges, court order, administrative subpoena or order. 
 Notwithstanding the foregoing, in the event a Party is required to make a disclosure
of the other Party’s Confidential Information pursuant to Section 12.2(a) or 12.2(d), such Party shall promptly notify the other Party such required disclosure and shall use reasonable efforts to obtain, or to assist the other Party in
obtaining, a protective order preventing or limiting the required disclosure. 
 12.3 Technical Publication. The JSC shall prepare a
plan for publication of the results of studies carried out under this Agreement and oversee the Parties’ activities thereunder. Each Party shall conduct its publication activities with respect to Compounds and Licensed Products in accordance
with such plan. Virobay may not publish peer reviewed manuscripts, or give other forms of public disclosure such as abstracts and presentations, of results of studies carried out under this Agreement, or otherwise related to Compounds and Licensed
Products, without prior review and approval by LEO, except to the extent required by applicable Laws. 

  
 42 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Virobay shall provide LEO the opportunity to review and comment on any proposed publication that relates to a Compound or Licensed Product at least [* * *] days prior to its
intended submission for publication (or, in the case of abstracts or presentations, at least [* * *] Business Days prior to its intended submission date). LEO shall provide Virobay with its comments in writing, if any, within
[* * *] days after receipt of such proposed publication ([* * *] Business Days for abstracts or presentations). Virobay shall consider in good faith any comments thereto provided by LEO and shall comply with
LEO’s request to remove any and all of LEO’s Confidential Information from the proposed publication. In addition, Virobay shall delay the submission for a period up to [* * *] days in the event that LEO can demonstrate
reasonable need for such delay for the preparation and filing of a patent application. Virobay shall provide LEO a copy of the manuscript at the time of the submission. Each Party agrees to acknowledge the contributions of the other Party and its
employees in all publications as scientifically appropriate. 
 12.4 Publicity; Terms of Agreement. 

(a) The Parties agree that the material terms of this Agreement are the Confidential Information of both Parties, subject to the
special authorized disclosure provisions set forth in this Section 12.4. 
 (b) On or after a mutually agreed date following the
Effective Date, the Parties shall make a joint public announcement of the execution of this Agreement in a form mutually agreed by the Parties. 

(c) After release of such press release, if either Party desires to make a public announcement concerning the material terms of this
Agreement, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and approval (except as otherwise provided herein), such approval not to be unreasonably withheld,
except that in the case of a press release or governmental filing required by law, the disclosing Party shall provide the other Party with such advance notice as it reasonably can and shall not be required to obtain approval therefor. A Party
commenting on such a proposed press release shall provide its comments, if any, within [* * *] Business Days after receiving the press release for review. Neither Party shall be required to seek the permission of the other Party to
repeat any information regarding the terms of this Agreement that has already been publicly disclosed by such Party, or by the other Party, in accordance with this Section 12.4, provided such information remains accurate as of such time. 

(d) The Parties acknowledge that either or both Parties may be obligated to file under applicable Laws a copy of this Agreement with
the U.S. Securities and Exchange Commission or other Governmental Authorities. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of the commercial terms and sensitive technical terms hereof
and thereof to the extent such confidential treatment is reasonably available to such Party. In the event of any such filing, each Party will provide the other Party with a copy of this Agreement marked to show provisions for which such Party
intends to seek confidential treatment and shall reasonably consider and incorporate the other Party’s comments thereon to the extent consistent with the legal requirements, with respect to the filing Party, governing disclosure of material
agreements and material information that must be publicly filed. 

  
 43 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE 13 

TERM AND TERMINATION 

13.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 13,
shall remain in effect on a Licensed Product-by-Licensed Product and country-by-country basis, until the expiration of the Royalty Term of such Licensed Product in such country (the “Term”). Upon the expiration of the Royalty Term
for a Licensed Product in a particular country, the licenses granted by Virobay to LEO under Section 2.1(a) with respect to such Licensed Product and such country shall become fully-paid, royalty free and exclusive. 

13.2 Unilateral Termination by LEO. LEO may terminate this Agreement in its entirety for any or no reason upon [* * *]
days written notice to Virobay. In addition, LEO may terminate this Agreement on [* * *] days written notice to Virobay if, in LEO’s reasonable belief, the Compound poses an unacceptable risk of harm to humans based upon
(i) preclinical safety data or (ii) the observation of serious adverse effects in humans after a Licensed Product has been administered to or taken by humans, such as during a clinical trial or after the launch of such Licensed Product.

 13.3 Termination by Either Party for Breach. 

(a) Breach. 
 (i)
Subject to Section 13.3(a)(ii), each Party shall have the right to terminate this Agreement upon written notice to the other Party if such other Party materially breaches its obligations under this Agreement and, after receiving written notice
from the non-breaching Party identifying such material breach in reasonable detail, fails to cure such material breach within [* * *] days from the date of such notice. 

(ii) If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by
the other Party in accordance with Section 13.3(a)(i), and such alleged breaching Party provides the other Party notice of such dispute within such [* * *] day period, then the non-breaching Party shall not have the right to
terminate this Agreement under Section 13.3(a)(i) unless and until the arbitrators, in accordance with Article 14, have determined that the alleged breaching Party has materially breached the Agreement and that such Party fails to cure such
breach within [* * *] days following such arbitrators’ decision. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties
shall continue to perform all of their respective obligations hereunder. 
 (b) Events of Default. Either of the following events
shall constitute an “Event of Default” under this Agreement: 
 (i) Virobay becomes the debtor of a case commenced
under Title 11 of the United States Code (the “Bankruptcy Code”) or under any successor or similar statute or regime (a “U.S. Virobay Bankruptcy”) and the license granted hereunder is rejected under

  
 44 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Section 365 of the Bankruptcy Code in a U.S. Virobay Bankruptcy notwithstanding the fact that LEO has elected to retain its rights to the license granted hereunder pursuant to
Section 365(n) of the Bankruptcy Code (“Section 365(n)”); or 
 (ii) Any of Virobay’s Affiliates that
owns, controls or is an exclusive licensee of any Ex-US Patents is the subject of a case or action under any foreign statute or regime that is similar or corresponding to the Bankruptcy Code in a country in the Territory other than the
U.S. that causes a material impairment of LEO’s rights in such license in any of the countries in the Territory. 
 (c) Events
of Default - Remedies. If an Event of Default pursuant to Section 13.3(b) shall have occurred and be continuing, LEO shall have, in addition to all other rights and remedies given it by this Agreement, those allowed by law and the
rights and remedies of a secured party under the Uniform Commercial Code as enacted in any jurisdiction in which either the Ex-US Patents may be located or is otherwise applicable and, without limiting the generality of the foregoing, LEO may
following notice (but without advertisement) sell at public or private sale or otherwise realize upon, the whole or from time to time any part of the Ex-US Patents, or any interest which Virobay may have therein, and after deducting from the
proceeds of sale or other disposition of the Ex-US Patents all reasonable expenses (including reasonable expenses for brokers’ fees and legal services), shall apply the residue of such proceeds toward LEO’s damages, it being understood
that the measure of such damages shall be those proximately caused by the termination of LEO’s exclusive license rights in the Field in the Territory. Any remainder of the proceeds after payment in full of the LEO’s damages shall be
paid over to Virobay. Notice of any sale or other disposition of the Ex-US Patents shall be given to Virobay at least [* * *] business days before the time of any intended public or private sale or other disposition of the
Ex-US Patents is to be made, which Virobay hereby agrees shall be reasonable notice of such sale or other disposition. At any such sale or other disposition LEO may, to the extent permissible under applicable law, purchase the whole or any part
of the Ex-US Patents sold, free from any right of redemption on the part of Virobay after such sale or other disposition, which right is hereby waived and released. 

13.4 Effect of Termination. Upon any termination (but not expiration) of this Agreement, all licenses granted to LEO under this
Agreement shall terminate, and the following shall apply: 
 (a) Wind-Down. Upon receipt of a termination notice from LEO during the
conduct of the Development Program, Virobay shall immediately commence winding down its activities under the Development Plan and shall use best efforts not to incur any additional Development expenses. 

(b) Regulatory Materials; Data. To the extent permitted by applicable Laws, LEO shall promptly transfer and assign to Virobay all
Regulatory Materials, Regulatory Approvals, and related data and Information relating to the Licensed Products and Compounds and shall treat the foregoing as “Confidential Information” of Virobay (and not of LEO) under Section 12;
provided that LEO will be allowed to retain any such materials that a Regulatory Authority requires LEO to retain under applicable Laws, and provided further that LEO shall have the right, and Virobay hereby grants to LEO, effective only upon
termination of this 

  
 45 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Agreement, a non-exclusive license to use any and all data generated by or on behalf of LEO or its Affiliates or sublicensees related to the Compounds and Licensed Products for the development
and commercialization of products other than Licensed Products. 
 (c) LEO License. LEO hereby grants to Virobay, effective upon such
termination, an exclusive, royalty-bearing, worldwide license (with the right to grant sublicenses through multiple tiers) under the LEO Technology as in existence as of the date of termination solely to research, Develop, make, have made, use,
sell, offer for sale, import and otherwise Manufacture or Commercialize Compounds and Licensed Products. Virobay shall pay to LEO a royalty on net sales of Licensed Products by Virobay or its Affiliate or sublicensee as follows:
[* * *]. Such royalties will be determined using the definition of Net Sales applied mutatis mutandis to sales by Virobay, its Affiliates and sublicensees, and the term of such royalty shall be the longer of, with respect to
a Licensed Product and country, (i) [* * *] years from First Commercial Sale of such Licensed Product in such country or (ii) the expiration of the last-to-expire Virobay Patent, Joint Patent or LEO Patent that covers the
composition of matter or method of use of such Licensed Product in such country for an Indication for which Regulatory Approval has been obtained. The terms of such royalties shall be as set forth in Sections 8.5(b)-(d) and 8.8 – 8.11 as
applied mutatis mutandis to LEO and its Affiliates and sublicensees. 
 (d) Trademarks. LEO shall assign to Virobay all right,
title and interest in and to the Product Marks (excluding any such marks that include, in whole or part, any corporate name or logo of LEO) throughout the Territory, at LEO’s expense. 

(e) Transition Assistance. In the event of termination of this Agreement by LEO pursuant to Section 13.2, LEO shall provide
reasonable assistance, to be billed to Virobay at a commercially reasonable rate to be negotiated by the Parties, as may be reasonably necessary for Virobay to commence or continue Developing, manufacturing and Commercializing the Licensed Products,
including without limitation, upon request of Virobay, using reasonable efforts to transfer any agreements or arrangements with distributors, suppliers or vendors that apply to the sale or supply of Licensed Products in the Terminated Countries.

 (f) Remaining Inventories. LEO shall complete any non-cancellable then in-process manufacturing runs and Virobay shall have the
right to purchase from LEO, at a price [* * *] all or part of the inventory of the Licensed Product held by or produced for LEO as of the effective date of termination of this Agreement. Virobay shall notify LEO whether Virobay
elects to exercise such right within [* * *] days after receiving notice from LEO reporting such inventory as of the date of such termination of this Agreement. 

13.5 Survival. Termination or expiration of this Agreement shall not affect any rights or obligations of the Parties under this
Agreement that have accrued prior to the date of termination or expiration. Notwithstanding anything to the contrary, the following provisions shall survive any expiration or termination of this Agreement: Sections 8.9, 8.10, 8.11, 9.1, 10.4,
12.1, 12.2, 12.4, 13.4 and 13.5 and Articles 11, 14 and 15. 

  
 46 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE 14 

DISPUTE RESOLUTION 

14.1 Disputes. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to
or in connection with this Agreement, including, without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of either Party by
written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting between the Parties’ respective Executive Officers. If the matter is not
resolved within [* * *] days following the written request for discussions, either Party may then invoke the provisions of Section 14.2. 

14.2 Arbitration. Any dispute, controversy, difference or claim which may arise between the Parties and not from the JSC, out of or in
relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance, application or termination of this Agreement) that is not
resolved pursuant to Section 14.1, except for a dispute, claim or controversy under Section 14.11, shall be settled by binding arbitration administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures then in effect
(the “JAMS Rules”), except as otherwise provided herein. Judgment upon the award may be entered in any court having jurisdiction thereof in accordance with the Convention on the Recognition and Enforcement of Foreign Arbitral Awards
of 1958. The arbitration will be conducted in New York, New York. 
 14.3 Arbitrators. The arbitration will be conducted by a panel
of three (3) neutral, independent and impartial arbitrators selected from a pool of arbitrators having experience in the development and commercialization of pharmaceutical products presented to the Parties by JAMS. Each Party shall select one
(1) arbitrator within [* * *] days after either Party invokes the provisions of Section 14.2, and the third arbitrator will be selected by mutual agreement of the two (2) arbitrators selected by the Parties (or by
JAMS in accordance with the JAMS Rules if such arbitrators fail to select the third arbitrator within [* * *] days after either Party invokes the provisions of Section 14.2). 

14.4 Governing Law. Resolution of all disputes arising out of or related to this Agreement or the validity, construction,
interpretation, enforcement, breach, performance, application or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York, U.S., excluding any conflicts
or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

14.5 Decision. The power of the arbitrators to fashion procedures and remedies within the scope of this Agreement is recognized by the
Parties as essential to the success of the arbitration process. The arbitrators shall not have the authority to fashion remedies which would 

  
 47 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
not be available to a U.S. federal judge hearing the same dispute. The arbitrators are encouraged to operate on this premise in an effort to reach a fair and just decision. Reasons for the
arbitrators’ decisions should be complete and explicit, including reasonable determinations of law and fact. The written reasons should also include the basis for any damages awarded and a statement of how the damages were calculated. Such a
written decision shall be rendered by the arbitrators following a full comprehensive hearing, no later than [* * *] following the selection of all three (3) arbitrators as provided for in Section 14.3. 

14.6 Award. Any award shall be promptly paid in U.S. dollars free of any tax, deduction or offset; and any costs, fees or taxes
incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the Party resisting enforcement. If as to any issue the arbitrators should determine under the applicable law that the position taken by a Party is
frivolous or otherwise irresponsible or that any wrongdoing they find is in callous disregard of law and equity or the rights of the other Party, the arbitrators shall also be entitled to award an appropriate allocation of the adversary’s
reasonable attorney fees, costs and expenses to be paid by the offending Party, the precise sums to be determined after a bill of attorney fees, expenses and costs consistent with such award has been presented following the award on the merits. Each
Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 14. The award shall include interest from the date of any damages incurred for breach of the Agreement, and from the date of the award until paid in
full, at a rate fixed by the arbitrators. With respect to money damages, nothing contained herein shall be construed to permit the arbitrators or any court or any other forum to award punitive or exemplary damages. By entering into this agreement to
arbitrate, the Parties expressly waive any claim for punitive or exemplary damages. The only damages recoverable under this Agreement are compensatory damages. 

14.7 Costs. Except as set forth in Section 14.6, each Party shall bear its own legal fees. The arbitrators shall assess their
costs, fees and expenses against the Party losing the arbitration unless they believe that neither Party is the clear loser, in which case the arbitrators shall divide their fees, costs and expenses according to their sole discretion. 

14.8 Injunctive Relief. Provided a Party has made a sufficient showing, the arbitrators shall have the freedom to invoke, and the
Parties agree to abide by, injunctive measures after either Party submits in writing for arbitration claims requiring immediate relief. Additionally, nothing in this Article 14 will preclude either Party from seeking equitable relief or interim or
provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the
interests of such Party or to preserve the status quo pending the arbitration proceeding. 
 14.9 Confidentiality. The arbitration
proceeding shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrators to make) any public
announcement with respect to the proceedings or decision of the arbitrators without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the
arbitrators, except as required in connection with the enforcement of such award or as otherwise required by applicable law. 

  
 48 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 14.10 Survivability. Any duty to arbitrate under this Agreement shall remain in effect
and be enforceable after termination of this Agreement for any reason. 
 14.11 Patent and Trademark Disputes. Any dispute,
controversy or claim relating to the scope, validity, enforceability or infringement of any Patent covering the manufacture, use, importation, offer for sale or sale of any Licensed Product or of any trademark rights relating to any Licensed Product
shall be submitted to a court of competent jurisdiction in the country in which such Patent or trademark rights were granted or arose. 

ARTICLE 15 

MISCELLANEOUS 
 15.1
Entire Agreement; Amendment. This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between
the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof, including the
Confidentiality Agreement. The foregoing shall not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under the Confidentiality
Agreement. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement. No subsequent alteration, amendment,
change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 

15.2 Rights in Bankruptcy. 

(a) All rights and licenses granted under or pursuant to this Agreement by one Party to the other are, for all purposes of the
Bankruptcy Code, licenses of rights to “intellectual property” as defined in the Bankruptcy Code, and, in the event that a case under the Bankruptcy Code is commenced by or against either Party (the “Bankrupt Party”), the
other Party shall have all of the rights set forth in Section 365(n) to the maximum extent permitted thereby. During the Term, each Party shall create and maintain current copies to the extent practicable of all such intellectual property.
Without limiting the Parties’ rights under Section 365(n), if a case under the Bankruptcy Code is commenced by or against the Bankrupt Party, the other Party shall be entitled to a copy of any and all such intellectual property and all
embodiments of such intellectual property, and the same, if not in the possession of such other Party, shall be promptly delivered to it (i) before this Agreement is rejected by or on behalf of the Bankrupt Party, within
[* * *] days after the other Party’s written request, unless the Bankrupt Party, or its trustee or receiver, elects within [* * *] days to continue to perform all of its obligations under this Agreement, or
(ii) after any rejection of this Agreement by or on behalf of the Bankrupt Party, if not previously delivered as provided under clause (i) above. All rights of the Parties under this Section 15.2 and under Section 365(n) are in
addition to and not in substitution of any and all other rights, powers, and remedies that each party may have under this Agreement, the 

  
 49 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Bankruptcy Code, and any other applicable Laws. The non-Bankrupt Party shall have the right to perform the obligations of the Bankrupt Party hereunder with respect to such intellectual property,
but neither such provision nor such performance by the non-Bankrupt Party shall release the Bankrupt Party from any such obligation or liability for failing to perform it. 

(b) The Parties agree that they intend the foregoing non-Bankrupt Party rights to extend to the maximum extent permitted by law and any
provisions of applicable contracts with Third Parties, including for purposes of the Bankruptcy Code, (i) the right of access to any intellectual property (including all embodiments thereof) of the Bankrupt Party or any Third Party with whom
the Bankrupt Party contracts to perform an obligation of the Bankrupt Party under this Agreement, and, in the case of the Third Party, which is necessary for the Development, Regulatory Approval and Manufacture of Licensed Products and (ii) the
right to contract directly with any Third Party described in (i) in this sentence to complete the contracted work. 
 (c) Any
intellectual property provided pursuant to the provisions of this Section 15.2 shall be subject to the licenses set forth elsewhere in this Agreement and the payment obligations of this Agreement, which shall be deemed to be royalties for
purposes of the Bankruptcy Code. 
 (d) The Parties intend that the foreign equivalents to the Bankruptcy Code and
Section 365(n) thereunder in any country in the Territory shall be construed in a manner to give effect to as close to the same substantive outcome that could possibly be effected to the full extent that the Laws in such jurisdiction permit the
non-Bankrupt Party to effect such outcome consistent with the effect of under Section 365(n) in the United States. 
 (e)
Notwithstanding anything to the contrary in Article 9, in the event that Virobay is the Bankrupt Party, LEO may take appropriate actions in connection with the filing, prosecution, maintenance and enforcement of any Virobay Patent licensed to
LEO under this Agreement without being required to consult with Virobay before taking any such actions, provided that such actions are consistent with this Agreement. 

15.3 Force Majeure. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that
such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the
nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure shall include conditions beyond the control of the Parties, including an act of God, war, civil commotion, terrorist act, labor
strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, and failure of plant or machinery (provided that such failure
could not have been prevented by the exercise of skill, diligence, and prudence that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of undertaking under the same or similar circumstances).
Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party. If a force majeure persists for more than [* * *] days, then the Parties will discuss
in good faith the modification of the Parties’ obligations under this Agreement in order to mitigate the delays caused by such force majeure. 

  
 50 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 15.4 Notices. Any notice required or permitted to be given under this Agreement shall
be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 15.4,
and shall be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by confirmed facsimile or a reputable courier service, or (b) five (5) Business Days after mailing, if mailed by first class
certified or registered airmail, postage prepaid, return receipt requested. 
  

			
	If to Virobay:	    	Virobay, Inc.
		    	1490 O’Brien Drive
		    	Menlo Park, CA 94025-1432
		    	Attn: [* * *]
		    	Fax: [* * *]
	
	With a copy to (which shall not constitute notice):
		
		    	Hogan Lovells US LLP
		    	525 University Ave, 3rd Floor
		    	Palo Alto, CA 94301
		    	Attn: [* * *]
		    	Fax: [* * *]
		
	If to LEO:	    	LEO Pharma A/S
		    	55, Industriparken
		    	2750 Ballerup
		    	Denmark
		    	Attn: [* * *]
		    	Fax: [* * *]
	
	With a copy to (which shall not constitute notice):
		
		    	Cooley LLP
		    	3175 Hanover Street
		    	Palo Alto, California 94304
		    	USA
		    	Attn: [* * *]
		    	Fax: [* * *]

 15.5 No Strict Construction; Headings. This Agreement has been prepared jointly by the Parties and
shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article
and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or 

  
 51 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
expand on the meaning of the language contained in the particular Article or Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and
the word “or” is used in the inclusive sense (and/or). The term “including” as used herein means including, without limiting the generality of any description preceding such term. 

15.6 Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written
consent of the other, except that a Party may make such an assignment or transfer without the other Party’s consent to its Affiliates or to a Third Party successor to substantially all of the business of such Party to which this Agreement
relates (such Third Party, an “Acquiror”), whether in a merger, sale of stock, sale of assets or other transaction. Any successor or assignee of rights and/or obligations permitted hereunder shall, in writing to the other Party,
expressly assume performance of such rights and/or obligations. The Virobay Technology, in the case of Virobay as assignor or transferor, or the LEO Technology, in the case of LEO as assignor or transferor, shall exclude any Patents and Information
Controlled by any Acquiror (or any Affiliate thereof, excluding a Party hereto as a result of such transaction) prior to the acquisition or developed outside of any activities under this Agreement. Any permitted assignment shall be binding on the
successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 15.6 shall be null, void and of no legal effect. 

15.7 Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its
Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any
breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such
Party’s Affiliate. 
 15.8 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and
to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 15.9
Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this
Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the
Parties when entering this Agreement may be realized. 
 15.10 No Waiver. Any delay in enforcing a Party’s rights under this
Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver
relating to a particular matter for a particular period of time. 
 15.11 Independent Contractors. Each Party shall act solely as an
independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners,
principal and agent, or joint-venture partners between the Parties. 

  
 52 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 15.12 English Language; Governing Law. This Agreement was prepared in the English
language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed
under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state. The Parties hereto submit to the exclusive jurisdiction of the state and federal
courts of the State of New York. 
 15.13 Counterparts. This Agreement may be executed in one (1) or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 {Signature page follows} 

  
 53 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 IN
WITNESS WHEREOF, the Parties have executed this Development and License Agreement by their duly authorized officers as of the Effective Date. 

 

									
	LEO PHARMA A/S	 		 	VIROBAY INC.
					
	By:	 	 [* * *]
	 		 	By:	 	 [* * *]

					
	Name:	 	[* * *]	 		 	Name:	 	[* * *]
					
	Title:	 	[* * *]	 		 	Title:	 	[* * *]

 Signature Page to Development and License Agreement 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 LIST OF EXHIBITS: 
  

			
	Exhibit A:	  	VBY-891 Structure
		
	Exhibit B:	  	Virobay Patents as of the Effective Date
		
	Exhibit C:	  	VBY-285 Structure
		
	Exhibit D:	  	Initial Development Plan
		
	Exhibit E:	  	Form of Non-Disturbance Agreement

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 EXHIBIT A: 

VBY-891 Structure 

[* * *] 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 EXHIBIT B: 

Virobay Patents as of the Effective Date 

[* * *] 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 [* * *] 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 EXHIBIT C: 

VBY-285 Structure 

[* * *] 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 EXHIBIT D 

Initial Development Plan 

{See following page} 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 [* * *] 

] 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit E 

Form of Non-Disturbance Agreement 

NON-DISTURBANCE AGREEMENT 

THIS AGREEMENT, made as of this      day of             ,
201    , by and among Virobay Inc. (“Licensor”) and [Name of Licensee] (“Licensee”), as licensor and licensee, respectively, under the License Agreement (as defined below), and LEO Pharma A/S (“Secured
Party”), holder of the Security Interest (as defined below). 
 W I T N E S S E T H: 

WHEREAS, Licensor and Licensee are parties to that certain [License Agreement] dated
            , 20    , as it may thereafter be amended (the “License Agreement”), under which Licensor granted a license under certain intellectual property
owned or controlled by Licensor (the “Intellectual Property”) for the term and upon the conditions set forth therein; and 

WHEREAS, Licensor has granted the Secured Party a security interest in some or all of the Intellectual Property (the “Security
Interest”) pursuant to that certain Development and License Agreement, by and between Licensor and Secured Party, dated December     , 2011, as it may thereafter be amended (the “Security Agreement”); and 

WHEREAS, Licensee has requested that Secured Party agree not to disturb Licensee’s rights in the Intellectual Property in the event that
upon an Event of Default (as such term is used in the Security Agreement), Secured Party takes possession of, sells, assigns, grants a license with respect to (other than licenses or sublicenses that Secured Party is authorized to grant in its
capacity as a licensee pursuant to the Security Agreement or any other agreement with Licensor), or otherwise exercise its rights and remedies under the Security Agreement with respect to all or any portion of the collateral constituting
Intellectual Property (in each case, a “Foreclosure”). 
 NOW, THEREFORE, in consideration for the foregoing and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and of the mutual benefits to accrue to the parties hereto, it is hereby declared, understood and agreed as follows: 

1. Secured Party consents to the License Agreement. 

2. In the event of a Foreclosure, it is agreed as follows: 
  

	 	(a)	Any transfer of the Intellectual Property to Secured Party or any other purchaser at a secured party’s sale or other disposition (a “Successor Licensor”) shall be subject to and not free and clear of the
license(s) granted to the Licensee pursuant to the License Agreement. 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(b)	Provided that Licensee is not in material breach of the License Agreement, neither Secured Party nor any Successor Licensor will disturb, diminish or interfere with the rights of Licensee under the License Agreement,
including any sublicenses granted or permitted to be granted thereunder. 

  

	 	(c)	Provided that Licensee is not in material breach of the License Agreement, Secured Party undertakes that it shall ratify and perform, or shall cause to be ratified and performed by Successor Licensor, all of
Licensor’s duties and obligations to Licensee under the License Agreement and shall be bound, or shall cause the Successor Licensor to be bound, to Licensee under all of the terms, covenants and conditions of the License Agreement for the
remaining balance of the term thereof, with the same force and effect as if Secured Party or Successor Licensor, as the case may be, were the Licensor under the License Agreement. 

 

	 	(d)	Notwithstanding the foregoing, neither Secured Party nor any Successor Licensor who acquires an interest in the Intellectual Property or the License Agreement as a result of any such Foreclosure or other enforcement
action or proceeding (the date on which the Secured Party, Successor Licensor, or such other party acquires such interest, hereinafter called the “Acquisition Date”) shall be (i) liable for any act or omission of Licensor under the
License Agreement or otherwise or for any damages arising as a result of a breach of the License Agreement by the Licensor, in either case occurring prior to the Acquisition Date; (ii) liable for the return of any payments made by the Licensee
to the Licensor under the License Agreement prior to the Acquisition Date; (iii) bound by any amendment, modification, alteration, assignment, transfer, cancellation, or early termination of the License Agreement made prior to the Acquisition
Date without Secured Party’s prior written consent; or (iv) required to perform or be liable for any affirmative obligations or covenants of the Licensor under the License Agreement that were required to be performed prior to the
Acquisition Date, or liable for any of the representations or warranties of the Licensor under the License Agreement that were made prior to the Acquisition Date, or liable for any indemnities of the Licensor with respect to events occurring prior
to the Acquisition Date. 

 3. This Agreement may be executed in one or more counterparts, all of which when taken together
shall constitute a single instrument. 
 4. This Agreement was prepared in the English language, which language shall govern the
interpretation of, and any dispute regarding, the terms of this Agreement. This Agreement and all disputes arising out of or related to this Agreement or any breach 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
hereof shall be governed by and construed under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a
different state. 
 [SEE ATTACHED SIGNATURE PAGES] 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 [Letterhead of LEO Pharma] 

 

			
	Virobay Inc.	  	4 January 2012
	Attn: [* * *]	  	
	1490 O’Brian Drive, Suite G	  	
	Menlo Park	  	
	CA 94025	  	
	USA	  	

 Development and License Agreement 

Dear [* * *] 
 We enclose the Agreement
now co-signed by LEO. 
 As discussed between you and [* * *], the Agreement has been signed and delivered by us subject to the
understanding that Virobay will use good faith, commercially reasonably efforts to [* * *], and to [* * *]. 
 We kindly
ask you to confirm the above by e-mail confirmation to us in response to this letter. 
 Yours sincerely, 

[* * *]  
 President & CEO 

 

							
	LEO Pharma A/S	  		  	Phone	  	+45 4494 5888
				
	Industriparken 55	  		  		  	
	2750 Ballerup	  		  	Internet	  	www.leo-pharm.com
	Denmark	  		  		  	
				
	VAT no. 56 75 95 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]